A NANO-DELIVERY SYSTEM GUIDED BY A MAGNETIC FIELD, SENSITIVE TO MICROENVIRONMENTAL CONDITIONS, AND FEATURING GRADUAL DRUG RELEASE.

Abstract

The invention relates to a magnetic field-guided stepwise drug release system (1) for the integrated achievement of controlled and stepwise release of therapeutic active substances to the target area. The system comprises a nano-carrier main body (2) containing magnetic nanoparticles (4), structurally and / or functionally separated therapeutic active substance release chambers (8, 14, 20), microenvironmentally sensitive release control structures associated with these chambers (10, 16, 22), inter-stage access interfaces (13, 19), inter-stage sequential access control structure (25), microenvironmental access channel (26), and inter-stage release delay barrier (28). Physical and / or chemical changes occurring in a release stage due to microenvironmental conditions alter the microenvironmental accessibility of the subsequent release stage via the inter-stage sequential access control structure (25).Once the subsequent release stage becomes accessible in terms of the microenvironment, the interstage release delay barrier (28) creates an additional and controllable resistance to the transition of the relevant therapeutic active substance reserve to effective release. Thus, the accessibility of the subsequent release stage to the microenvironment and the effective release of the therapeutic active substance are regulated as separate but functionally related control states. The nano-carrier main body (2) can be directed, concentrated and / or held in the direction of the target tissue region (35) under the magnetic effect created by the external magnetic field generating unit (32), magnetic field guiding element (33) and magnetic field concentrating element (34).

Description

1 TARIFF MAGNETIC FIELD-DIRECTED, MICROENVIRONMENTAL CONDITION RESPONSIVE AND GRADUAL DRUG RELEASE MECHANISM NANO-CARRIER SYSTEM Technological Field: 5 This invention describes targeted and controlled delivery and release of therapeutic active substances. systems, biocompatible nano-carrier structures, under the influence of magnetic field Guided and controllable carrier systems that can be held in the target area, adaptable to microenvironmental conditions. responsive material structures and gradual and / or sequential release of therapeutic active substances. This relates to technologies, particularly the delivery of the therapeutic active substance to non-target areas. limiting its distribution, concentrating the nano-carrier system in the target region. and / or retention of the therapeutic active substance contained within the nano-carrier. controlled release of reserves through separate release stages It is located in the field of nano-carrier systems for release. More specifically, the invention is a biocompatible 15-bit or ... a nano-carrier structure and a structure that imparts magnetic properties to that nano-carrier structure functional integration of components; external nano-carrier system The target is directed towards the target area under the influence of the generated magnetic field. increasing the density around the region and / or for a certain period of time It includes technologies aimed at keeping the area under control. Within this scope, 20 therapeutically effective... magnetic field relationship of material transport function and positional behavior of nano-carrier Control through this mechanism is carried out within the same system architecture. The invention also includes physical and / or environmental effects depending on the microenvironmental characteristics of the target region. structures sensitive to microenvironmental conditions with alterable chemical behavior via nano-carriers integration and the release of the therapeutically active substance in the said behavioral change 25 It relates to technologies used in controlling the release of offenders. Within this scope... permeability change, swelling, dissolution, bond separation, structural opening, therapeutic efficacy changes in the interaction between the material and the carrier structure and / or the microenvironment by modifying access to different regions within the nano-carrier The controlled oscillation mechanisms implemented relate to the technological field 30 of the invention. It is located within. The technological scope of the invention also includes the therapeutic active substance within a nano-carrier. Instead of being kept in a single homogeneous oscillating environment, they are structurally and / or functionally distinct from each other. 2 separated and containing multiple therapeutic agents with different release characteristics Multistage nano-carrier systems in which a material release chamber is created. It includes the material structure, permeability, and dissolution of the oscillation chambers in question. its behavior, its ability to retain the therapeutic active substance, and its response to microenvironmental conditions. controlled oscillation transition paths and / or surrounding barrier structures 5 by differentiating them in terms of therapeutic active substance in a single step, Instead of being released simultaneously and uncontrollably, they can be separated from each other. Technical arrangements for transmitting the oscillation through stages are also part of the invention. It falls within the scope of the technological field. The invention also relates to physical and / or chemical reactions occurring in an oscillation phase. the change only affects the release of the therapeutic active substance at that particular release stage. not only does it affect it, but it also affects the subsequent oscillation stage. the status of access to the microenvironment, the degree of access and / or access sequential access control between levels that can change the resistance created against the transition It relates to nano-carrier architectures. In this context, there are 15 different oscillation chambers. sequential access between levels with created inter-level access interfaces the regulatory structure, physical and / or chemical changes that occurred in the previous release stage The microenvironmental accessibility of the change and the subsequent oscillation stage. This creates a structural and functional relationship between the processes involved. The following Ensuring access to the microenvironment at the emission stage means that the emission in question is 20. the direct, simultaneous and therapeutic active substance reserve located at this level It does not necessitate uncontrolled release; oscillation between levels. followed by enabling microenvironmental access through a delay barrier. between the onset of effective release of the therapeutic active substance reserve and A controllable transition resistance can be created. Thus, 25 consecutive steps can be achieved between stages. The access regulation structure depends on the change that occurred in the previous oscillation stage. the microenvironmental accessibility status of the subsequent emission stage While performing the primary control function, it also regulates the oscillation delay between stages. the barrier to access subsequently leads to uncontrolled reserve of the therapeutic active substance. limiting its conversion to release and the initial delivery of the therapeutic active substance 30 It also performs a second control function that regulates the condition, speed and / or duration. This brings together these two control functions within the same nano-carrier architecture. Through its functional association, it is followed by the activation of an oscillation stage. 3 the release stage becoming accessible in terms of the microenvironment and effective release of the therapeutic active substance reserve in the subsequent release stage The transition to this state can be regulated as separate technical events. In this context, selective oscillation barriers, controlled oscillation transition paths, and inter-stage systems are used. access interfaces, sequential access management structure between levels, and 5 levels between levels structural changes occurring in an oscillation stage through an oscillation retardation barrier and / or microenvironmental reach of the subsequent release stage of the physicochemical change altering its state and the therapeutic active substance in the subsequent release phase the transfer through a separate control phase from the access change in question The carrier systems that can be arranged are within the technical scope of the invention. 10 Within the scope of this invention, staged and / or sequential release applies only to the therapeutically active substance. dispersed in different amounts within the nano-carrier or in different physical regions It is not a structure based on holding different therapeutic active substance reserves; their relative positions affect the release of therapeutic active substances from the reserves in question. compartments, microenvironmentally sensitive oscillation regulation structures, selective oscillation 15 barriers, controlled oscillation transition channels, inter-level access interfaces, Inter-stage sequential access control structure, staged oscillation control layer, and physical, chemical and It relates to an integrated oscillation architecture organized through functional relationships. The subject in architecture is that different release levels only affect the therapeutically active substance at different rates. Instead of functioning as independent zones that release radiation at certain times, the previous oscillation the subsequent release of physical and / or chemical changes occurring at this stage the level can change the microenvironmental accessibility status and subsequent accessibility of therapeutic active substance delivery at the release stage 25 A control relationship is established. Thus, different oscillation levels conditions for accessibility in terms of microenvironment, therapeutic active substance the initial conditions of the transmission, transmission speeds and / or oscillation times differ from each other It can be differentiated and successive oscillation stages are defined by the nano-carrier. It can be functionally related by its structural architecture. 30 Accordingly, the invention relates to positional navigation achieved through a magnetic field. and its retention function in the target region, depending on the microenvironmental conditions of the target region. Temporal oscillation control is achieved using the same nano-carrier architecture. 4 It is related to the systems in which it is brought together. The magnetic field of the nano-carrier therapeutic applications of microenvironmentally sensitive structures in controlling their spatial behavior. in controlling the release behavior of the active substance and its access between levels in the separation of successive oscillation phases of regulating structures The multi-component nano-carrier technologies used are within the technical scope of the invention. It is located. The invention also describes the structural and functional relationships between different oscillation chambers. by regulating the release sequence and release rate of the therapeutic active substance This relates to nano-carrier architectures where the release time can be controlled. in a frame, in an oscillation compartment or a barrier associated with such oscillation compartment, 10 oscillation following a change in the binding, interface, or transition structure. It can change the access of the microenvironment to the compartment; different oscillation compartments it can exhibit different response characteristics and the transition between oscillation stages is nano- systems where the carrier's physical and / or chemical architecture can be regulated The invention is evaluated within the technological field to which it relates. 15 The technological field of the invention, given its specified characteristics, is nanotechnology and biomaterials. technologies, magnetic nanostructures, polymeric microstructures sensitive to microenvironmental conditions delivery systems, targeted therapeutic active substance delivery technologies, and It is located at the intersection of controlled drug delivery systems; especially magnetic ones. Positional control, target area retention, microenvironmental condition-dependent oscillation control, 20 Inter-level access regulation and multiple releases of the therapeutic active substance. the functions of transferring data gradually and / or sequentially through the compartment are the same Techniques for integrated implementation within a nano-carrier architecture. It includes systems. State of the Art: 25 In cancer treatment and similar applications where therapeutic active substances are administered systemically. In treatment approaches, the active substance reaches different parts of the organism via the circulatory system. distribution to the affected areas ensures that the applied therapeutic active substance is only delivered to the targeted tissue. This can make it difficult to concentrate the treatment in the target area and also affect non-target tissues therapeutically. This can lead to exposure to the active substance. This situation results in 30% of the target area being exposed to the active substance. to create a concentration of the active substance that can produce a therapeutic effect and by maintaining the concentration in question for a certain period of time, occurrences in off-target areas There is a technical aspect to limiting potential exposure to unwanted active substances. This creates a need for control. Therefore, the therapeutic active substance transportation, delivery to the target area, concentration and / or retention in the target area and controlled release from the carrier structure are drug delivery technologies. It constitutes one of the main areas of study. In the current state of the art, polymeric 5-bit materials are used for the transport of therapeutically active substances. nanoparticles, lipid-based carriers, inorganic nanoparticles, core-shell structured nanoparticles nano-carriers, porous carrier structures, and the combination of different materials Composite nano-carrier systems are created and used. In these systems, therapeutic The active ingredient can be physically confined within the carrier structure, attached to the carrier material. can bind, be held within pores or voids, or exhibit various physical characteristics. and / or retention within the carrier through chemical interactions It is possible. However, the ability of a therapeutic active substance to be transported within a nano-carrier is a key feature. The issue is the controlled and sufficient amount of the active substance in the targeted anatomical region. It alone does not ensure that it can be used in this way. 15 occurs during circulation. inbound dispersal, interaction with biological barriers, accumulation in off-target areas, carrier the removal of the system from the biological environment and its journey from the carrier to the target region Factors such as potential loss of therapeutic active substance that may occur beforehand, in the target area the amount of active substance available and the period during which that amount can be maintained It can have an effect. Therefore, in the known technique, different 20 nano-carrier systems are used. Various approaches have been developed to add targeting features. One of these approaches is the magnetic transfer of nano-carrier systems that carry therapeutic active substances. It is the integration of components exhibiting magnetic properties. Magnetic nanostructures, externally Therapeutic active substances because they can interact with a magnetic field that is generated. Orienting the supporting structures towards a specific area, 25 around the target area increasing their density and / or keeping them in the region for a certain period of time It can be used in systems targeting this purpose. In this context, especially iron oxide-based systems. magnetic nanoparticles combined with polymeric or different carrier materials The nano-carrier structures to which it is brought are known. Magnetic orientation approach controls the positional behavior of the nano-carrier system 30 While providing a technical means for its production, it also provides a technical means for the production of the therapeutically active substance. Under what conditions, at what speed, in what quantity, and for how long is it released from the carrier? Checking that it will be released presents a separate technical problem. Nano- 6 the presence or concentration of the carrier in the target region, the carrier it carries the therapeutic active substance is released in the relevant region with the desired release profile. It does not automatically lead to its release. The nano- therapeutic active substance Separation of the carrier before reaching the target area can increase off-target exposure, Release of a large quantity shortly after reaching the target area 5 the initial oscillation rises excessively and subsequently within the nano-carrier structure This can lead to a lack of sufficient reserves of active ingredients. In contrast... Slower-than-necessary release of the therapeutic active substance at the target site is necessary. This leads to the inability to achieve the desired concentration of the active substance within the desired time interval. It can open. 10 Controlled release of therapeutic active substance to address these problems. Systems have been developed. In controlled oscillation systems, the structural integrity of the carrier material... properties, permeability, dissolution behavior, porosity, therapeutic active substance the physical and / or chemical interactions it establishes and its responses to environmental conditions using the behavior of releasing the therapeutic active substance from the carrier 15 The aim is to change it. The current state of the art also includes environmentally sensitive nano-carrier systems. These systems include pH, temperature, redox conditions, enzymatic activity, or a change in one or more of similar microenvironmental variables As a result, physical and / or chemical changes occur in the load-bearing structure. 20 This can be achieved through changes such as swelling or dissolution of the carrier. changes in permeability, breakdown of certain bonds, changes in surface properties, or This manifests as a weakening of the interaction between the therapeutic active substance and the carrier. it can exit and thus the therapeutic active substance is released from the carrier structure. It is being attempted to be controlled. 25 pH-sensitive nano- for exploiting the microenvironmental characteristics of tumor tissue. Carrier systems are also included within the known technical framework. These systems have a specific pH. polymeric structures, linker groups, coating layers or that respond to conditions Similar sensitive components can be used, and they are adaptable to changes in environmental conditions. Modifying the release behavior of the therapeutic active substance from the carrier 30 that is intended. In the current state of the art, components exhibiting magnetic properties are affected by pH or other factors. microenvironmentally sensitive carrier components within the same nano-carrier system 7 There are also structures in which it is used. In such structures, the magnetic component is nano- It enables the carrier to interact with an external magnetic field while being sensitive to microenvironmental conditions. The carrier portion may affect the release of the therapeutic active substance. Therefore, a magnetically-oriented compound is a drug sensitive to microenvironmental conditions. Bringing it together with the carrier alone solves all of the technical problems in question. 5 It does not constitute a solution that eliminates it. Specifically, spatial targeting and temporal oscillation control are independent of each other. Implementing them as functions creates a significant technical limitation. It is able to bring about the magnetic field to the position of the nano-carrier system in the target region and It can affect its concentration, and the microenvironmentally sensitive component is therapeutic 10 It can initiate or modify the release of the active substance; however, these two functions... The presence of the therapeutic active substance within the same nano-carrier ensures accuracy in the target region. separate and structurally related oscillation phases It does not automatically ensure controlled transmission throughout. A carrier with a single oscillation medium or predominantly uniform oscillation behavior 15 In these structures, a significant portion of the therapeutic active substance is found under similar microenvironmental conditions. It can be subject to the same oscillation mechanism underneath. In such a case, the target the amount of therapeutic active substance requested to be released in the region in the initial phase the amounts of active substance intended to be transferred in subsequent time intervals Their varying oscillation behaviors can make them difficult to manage. This 20 As a result, the initial oscillation is high, while the sustained oscillation is insufficient. rapid depletion of the active substance reserve in the carrier or total release technical issues such as the inability to regulate the duration in a way that is consistent with the targeted therapeutic process Limitations may occur. Similarly, the therapeutic active substance is homogeneously distributed within the nano-carrier structure at 25 where it is distributed and oscillation largely depends on the behavior of a single carrier region. In these structures, different parts of the therapeutic active substance have different release patterns. Control by its characteristics may be limited. The first therapeutic active substance. a specific amount of active substance followed by a different release behavior with a release behavior and subsequently a longer-lasting reserve of active substance or 30 in order for it to be released with an oscillation behavior depending on different conditions oscillation behaviors structurally and / or functionally within the nano-carrier They need to be able to be separated from each other. 8 In addition, a nano-carrier structure sensitive to microenvironmental conditions requires only a single unit. its behavior based on a response threshold or a single release mechanism, in the target tissue non-homogeneity of microenvironmental conditions or changes over time in this case, detailed control of the oscillation behavior This can make things more difficult. The nano-carrier's encounter with specific microenvironmental conditions 5 As a result, the entire reserve of therapeutic active substance it carries undergoes the same release process. Instead of entering each other, different amounts of active substance are released separately. kept in compartments and these compartments have different permeability, solubility, bonding properties. its decomposition, microenvironmental response and / or transition characteristics, release a technical requirement for more detailed regulation of its behavior 10 It constitutes. On the other hand, phased release simply means releasing different amounts of the therapeutic active substance. This is achieved by loading it onto a nano-carrier or holding it in different layers. Creating a functional dependency between oscillation stages alone It does not provide. The release sequence and release of different therapeutic active substance reserves 15 its characteristics determined by the physical and / or chemical architecture of the nano-carrier The ability to determine; the subsequent structural change occurring in one oscillation stage Ability to change access to the microenvironment in the oscillation chamber; different oscillations their compartments to different microenvironmental conditions and / or different responses It can have its own characteristics and the transition between oscillation compartments has different barriers 20 and its ability to be regulated through transfer properties, the delivery of the therapeutic active substance Technical importance in terms of being controlled in separate stages. It carries. The activation of one release phase triggers all subsequent therapeutic active ingredients. The direct entry of reserves into the same release process also controls gradual release. 25 This can limit its feasibility. Therefore, what happens in an oscillation chamber as a result of the physical and / or chemical change that occurs, to the subsequent release chamber access to the microenvironment is provided, and the subsequent therapeutic effect of that access not to cause the immediate and uncontrolled release of the reserve of material; The transfer between stages has different permeability, resistance and / or delay. 30 The ability to further regulate these features through structures that exhibit these characteristics is a technical requirement. It constitutes. 9 In this context, only the reservoir of multiple therapeutic active substances, release chamber or the presence of the carrier layer within the same nano-carrier structure, these reserves or a functionally dependent, stepped and / or sequential oscillation between oscillation chambers This does not mean that an oscillation relationship has been established. Physically... the reserves of therapeutically active substances separated as a whole are divided at different rates or at different 5 While it is possible to release it at time intervals, the previous release physical and / or chemical changes occurring at this stage and the subsequent oscillation defined between the level becoming accessible in terms of the microenvironment. When no structural relationship exists, the oscillation stages operate independently of each other. They can remain in the nature of oscillation zones. In this respect, there are 10 technical issues that need to be resolved. The problem is not simply that different reservoirs of therapeutic active substances have different release rates, or not releasing them under their specified periods; but causing a release phase to be activated Which structural pathway leads to the next release stage of the microenvironmental interaction? that it will be transmitted via, tracking the change that occurred in the previous oscillation stage. how the emission level will change the microenvironmental accessibility status 15 and the therapeutic active ingredient in the subsequent release phase that becomes available under what additional transition condition and / or transition resistance is the reserve effectively released? The fact that its passage can be determined by the nano-carrier architecture is the key. Therefore, the truth is... In terms of establishing gradual and sequential oscillation control, the oscillation... It is not enough for the stages to be separated only physically; the previous oscillation 20 physical and / or chemical changes occurring at this stage and the subsequent oscillation a functional link and word between the microenvironmental accessibility status of the level the issue is the accessibility status and the subsequent release of the therapeutic active substance reserve. Furthermore, establishing a controllable transitional relationship between them is of technical importance. It carries. 25 Current approaches also involve increasing the nano-carrier density in the target region. how the therapeutic active substance remains in the target region during the time the nano-carrier is located There is a need to jointly monitor whether it will be released. Nano- the carrier system is directed to the target area via a magnetic field or by word While keeping the subject in the region provides spatial control, the different 30 therapeutic active substances its release in the release phases via nano-carrier architecture also It needs to be adjusted. Therefore, spatial targeting and temporal oscillation are important. control as complementary functions within the same technical system Regulation is important. However, in nano-carrier systems, combining different functions makes the carrier more versatile. This can increase the complexity of the structure. Nano-carriers of magnetically-enabled components. its location inside, release chambers containing therapeutic active ingredient reserves, 5 distribution of structures sensitive to microenvironmental conditions, access between the compartments in question. pathways, selective oscillation barriers, and structures regulating transitions between levels are suitable. When not associated in this way, despite having magnetic orientation properties the release not occurring in the desired sequence and speed or being sensitive to microenvironmental conditions Despite the release being achieved, there was insufficient nano-carrier density in the target region and 10 It may not be possible to create a sustained controlled release simultaneously. Therefore, the technical need in the current state of the art is only the therapeutic active substance. Creating a nanoparticle capable of carrying a magnetic field only to that nanoparticle The enhancement of this feature, an oscillation that is only sensitive to microenvironmental conditions. the use of the mechanism or only one of the therapeutic active substances 15 The technical requirement is not the distribution of the nano-carrier to the carrier region. with positional control regarding its orientation and / or retention in the target area release of the therapeutic active substance through separate release stages Temporal control over the release of the nano-carrier depends on its physical and / or chemical properties. It is the integration of structures defined within its architecture through structural relationships. 20 Accordingly, several therapeutic active substances with different release characteristics can be kept in the excess oscillation chamber; the oscillations of the said oscillation chambers their behaviors can be separated from each other; oscillation chambers are subject to microenvironmental conditions an oscillation in which the physical and / or chemical reactions they produce can be differentiated; The change occurring at this stage affects the subsequent oscillation stage in terms of microenvironment. 25 can directly or indirectly alter media access; subsequent oscillation the level uncontrollably as soon as the access in question is realized different transition and / or delay characteristics can be created that limit its emptying. and this entire oscillation architecture involves the magnetic orientation of the nano-carrier and integrated nano-carrier 30 that can work together with the function of being held in the target region There are technical needs for the systems. Within the scope of this technical requirement, events that may occur before reaching the target area Limiting the loss of therapeutic active substance in the target region at the initial stage. 11 controlled administration of the required amount of therapeutic active substance, followed by the process involves the delivery of the active substance through separate release stages. the maintenance of the reserves of therapeutic active substances within the nano-carrier is unique. limiting consumption in stages, subsequent oscillations from one oscillation stage The transition to stage 5 is regulated by the nano-carrier architecture and oscillation. The correlation of behavior with the microenvironmental conditions of the target region is interconnected. These are related technical problems. In conclusion, in the current state of the art, magnetic targeting systems are used in microenvironments. Condition-sensitive nano-carrier systems, multilayer carrier structures, and controlled Therapeutic active substance delivery systems, individually or in various combinations. 10 However, the technical requirements for these functions are as follows: not only are they limited to being present together within the same nano-carrier; nano- positional control of the carrier through a magnetic field, the release behavior and therapeutic active substance differ depending on the microenvironmental condition. The temporal control of the transfer from the oscillation compartments is a defined structural relationship 15 It is aimed at being operated within it. In particular, the therapeutic active substance is separated from each other. held in separate oscillation compartments, these oscillation compartments have selective oscillation. separated by barriers and controlled access structures, in a swing phase the subsequent release stage of the structural and / or physicochemical change that occurs microenvironmental access can be altered and the transition between levels is different 20 a nano-carrier that can be regulated via transition resistors and / or retarder structures The need for technical development in the creation of architecture continues. This Therefore, positional targeting and temporal oscillation control are independent of each other. Instead of performing these functions as magnetic guidance and target area holding function, microenvironmentally sensitive activation, inter-stage access 25 control and controlled delivery of the therapeutic active substance within the same carrier architecture integrated systems that transform technical elements into functionally related elements It needs to be improved. The purpose of the invention: The main purpose of the invention is to create an external 30 nano-carrier system carrying therapeutic active substances. being able to be directed to the target area under the influence of a magnetic field, target area increasing its density in the surrounding area and / or maintaining it in the target region, oscillation behavior depending on the microenvironmental conditions of the target region 12 the possibility of altering and transporting the therapeutic active substance in a single-step and uncontrolled manner instead of one oscillation, multiple oscillations that are structurally and / or functionally separated from each other. controlled, gradual and / or sequential release through the compartment The aim is to create an integrated system that operates within a nano-carrier architecture. Another aim of the invention is to target the therapeutically active substance using only nano-5 atoms. Instead of focusing on delivering the carrier to the target region, the focus is on the positional movement of the nano-carrier. Simultaneous monitoring of the behavior and temporal release behavior of the therapeutic active substance. The aim is to enable this. In this regard, the nano-carrier has magnetic components. By interacting with an external magnetic field, it is directed towards the target area, increasing the density around the target area and / or 10 in the said area retention; release of the therapeutic active substance within the nano-carrier. different oscillation chambers and sensitive to the microenvironmental conditions associated with those chambers structures, selective oscillation barriers, controlled oscillation transition paths, and stages The aim is to regulate the access structures between them based on their characteristics. Another aim of the invention is to deliver the therapeutic agent to the target area before the nano-carrier system reaches it. to limit the unwanted separation of the active substance from the carrier structure and the transported therapeutic active substance reserve should be as close as possible to the target region. The aim is to enable its use in the controlled release process that will be carried out. For this purpose... Stable retention and release of the therapeutic active substance within a nano-carrier. the correlation of its behavior with the microenvironmental conditions in which the nano-carrier is located and 20 loss of therapeutic active substance until the targeted microenvironmental conditions are met limiting barriers, binders, coatings and / or similar structural arrangements The aim is to create. Another aim of the invention is to analyze the microenvironmental characteristics of the target region and the off-target region. By taking advantage of the differences in the characteristics of the environments, the therapeutic active substance 25 The aim is to enable increased selectivity of release. In this context, pH in particular nano-carriers are structures that can respond to microenvironmental conditions, including changes. integration with architecture and swelling, disintegration occurring in the structures in question, permeability change, bond separation, structural opening and / or similar physical or chemical changes release of therapeutic active substance and / or subsequent release 30 can be used in controlling access to the microenvironment at the level that is intended. 13 Another objective of the invention is to deliver the therapeutically active substance within a single nano-carrier structure. Instead of being in a homogeneous oscillation environment, it exhibits different oscillations. in multiple therapeutic active substance release chambers with their own characteristics The aim is to ensure the regulation of different reservoirs of the therapeutically active substance. different oscillation starting conditions, oscillation speeds, oscillation durations, 5 subject to microenvironmental response characteristics and / or carrier-to-external transfer characteristics The aim is to ensure it can be retained. Another objective of the invention is to allow different release chambers to contain only the therapeutically active substance. Instead of being created as passive volumes into which they are physically divided, each oscillation The compartment is a functional structure that determines the release behavior of the therapeutic active substance. 10 The aim is to ensure that it is arranged accordingly. In this context, the material structure of the oscillation chambers, sensitivity to microenvironmental conditions, permeability, dissolution behavior, therapeutic efficacy its property of retaining the substance, its relationship with controlled release transition channels and / or the matter in question The properties of selective oscillation barriers surrounding the compartments are differentiated from each other. The aim is to generate the distinct oscillation characteristics. 15 Another objective of the invention is to expose different oscillation chambers to microenvironmental conditions simultaneously. And similarly, the goal is to create a nano-carrier architecture that does not necessarily require a similar response. In this context, emission chambers and / or microenvironmental conditions associated with said chambers condition-sensitive structures having different response characteristics and / or different response rates Therapeutic efficacy in a single oscillation chamber can be increased by 20 thanks to its configuration. the therapeutic active substance in a subsequent release chamber after substance delivery has begun so that the reserve can continue to be maintained and thus the release can be separated from each other. The aim is to implement this in stages. Another aim of the invention is to deliver the therapeutic active substance to the target region when the nano-carrier reaches it. the release of all or most of the reserves in a short period of time 25 instead, the initial oscillation and the subsequent oscillation stages are separated from each other. The aim is to ensure its separation. Thus, the therapeutic effect determined in the first release phase is achieved. after controlled transfer of the substance within the nano-carrier in subsequent release stages of the remaining therapeutic active substance reserves availability and successive release of total therapeutic active substance 30 The aim is to distribute it across the stages. Another objective of the invention is to achieve gradual and / or sequential oscillation only when different amounts loading of the therapeutic active substance onto a nano-carrier, therapeutic active substance 14 their reserves are stored in different carrier layers or in different passive layers not based on creating oscillation durations; the sequence of oscillations, oscillations the microenvironmental accessibility status of the stages and each oscillation physical characteristics of the nano-carrier in the delivery of the therapeutic active substance at the stage and / or to ensure that it can be determined by its chemical architecture. In this context, 5 the relative positions of the therapeutic active substance release chambers microenvironmentally sensitive oscillation regulation structures associated with oscillation chambers, selective oscillation barriers, controlled oscillation transition channels, inter-stage access interfaces, sequential access management structure between levels, incremental oscillation the control layer and the inter-stage oscillation retardation barrier are defined by each other. The aim is to organize them within structural and functional relationships. Thus, the previous the physical and / or chemical change that occurs during the release phase the accessibility status of the swing stage can be changed, the accessibility in question the direct release of the subsequent reserve of the therapeutic active substance following the change It is not synonymous with discontinuation and the relevant release of the therapeutic active substance is 15. an oscillation that can also be regulated through control structures belonging to its level The aim is to create its architecture. Another aim of the invention is to separate oscillation chambers only when different Organized as independent reserves that release emissions at different times. instead, the physical and / or chemical change occurring in an oscillation stage is followed by 20 direct or indirect access of the microenvironment to the oscillation stage The goal is to create a sequential access controlled oscillation architecture that can be modified. This a microenvironmentally sensitive structure associated with an oscillation chamber in the direction of selective permeability of the oscillation barrier and / or inter-level access interface change, swelling, dissolution, decomposition or alteration of structural integrity 25 resulting in increased access of the microenvironment to the subsequent release chamber. and / or is intended to be modified. Another purpose of the invention is to address the physical and / or abnormalities that occur in the previous oscillation stage. The microenvironment is transferred to the subsequent release chamber as a result of chemical change. Ensuring access to the subsequent therapeutic active substance reserve directly, equally 30 to limit the possibility of untimely and uncontrolled release and separating the release of therapeutically active substances through microenvironmental access between levels The goal is to create control stages that can be separated. For this purpose, the oscillation stages can be divided into distinct control phases. Inter-stage oscillation that can create different permeability and / or resistance to transmission. The use of delay barriers and controlled access structures; thus, previous the subsequent oscillation depending on the change occurring in the oscillation stage with the microenvironmental accessibility of the level in question The effective release state of the therapeutic active substance reserve located in the release stage is 5. a control relationship is also established between them The aim is to achieve this. Accordingly, in this invention, sequential oscillation is only intended to have different therapeutic effects. by releasing material reserves at successive time intervals not the implementation, but the accessibility status of the subsequent oscillation stage. with physical and / or chemical changes occurring in the release phase 10 therapeutic effects in the subsequent release phase that are associated with and made accessible The delivery of the active substance is also regulated via a defined resistance to passage. creating a functionally dependent oscillation chain The aim is to show the change that occurs in the first oscillation stage. the access condition of the second oscillation stage, 15 occurring in the second oscillation stage The change can affect the access condition of the third oscillation stage, and this corresponding to the delivery of the therapeutic active substance at each release stage. a nano- The aim is to create a structurally sound architecture. Another aim of the invention is to investigate the physical and / or chemical behavior of an oscillation stage. a structural and functional difference between the activation of the subsequent oscillation stage The goal is to create a connection. Thus, the oscillation sequence is only due to the passage of time. Instead of being determined by a passive process dependent on microenvironmental conditions, the nano-carrier is determined by microenvironmental conditions. its response, the accessibility between levels, and the differences between oscillation levels. The aim is to enable customization through the transition properties created. 25 Another objective of the invention is to investigate the oscillation of the microenvironment within the nano-carrier. by regulating access to these regions, the oscillation process begins with different oscillations. the ability to control the transitions between levels through the carrier architecture The aim is to provide this. In this context, it enables the entry of the microenvironment into the nano-carrier. structures, passageways reaching the relevant oscillation chamber, and the 30 between the oscillation chambers by functionally linking access interfaces with each other the effect of microenvironmental conditions on the release of therapeutic active substance by the carrier The aim is to transfer them to designated areas. 16 Another objective of the invention is to eliminate barriers, interfaces and / or oscillation zones located between oscillation zones. Transition structures as technical elements regulating the delivery of the therapeutic active substance. The aim is to ensure its use. The thickness, permeability, and pore structure of the structures in question, swelling property, dissolution behavior, physical integrity, and resistance to microenvironmental conditions. Different oscillations are achieved by varying the response and / or the transient resistance it generates. 5 the rates of therapeutic active substance delivery and / or release occurring from its compartments The aim is to make the initial conditions different from one another. Another objective of the invention is to enable the nano-carrier to be released from different release chambers. The delivery of the therapeutic active substance is only possible via a two-state release, either open or closed. Instead of exhibiting the behavior, the amount of oscillation, the oscillation speed and / or the oscillation duration is 10 The aim is to enable the modification of the nano-carrier architecture based on its properties. Thus, the initial oscillation amount can be adjusted to suit different application requirements, followed by... Different oscillations in terms of the transmission speed of the oscillation stages and the total oscillation duration. The aim is to create profiles. Another objective of the invention is to place magnetically-enabled components within a nano-carrier in just 15 millimeters. Instead of having an additional material that provides magnetic properties, the nano-carrier with a load-bearing architecture as a functional section that performs positional control The aim is to ensure the integration of magnetic components in nano- The orientation of the carrier under the influence of an external magnetic field, target region Contributing to increasing its density in the surrounding area and / or maintaining it in the target region 20 The aim is to arrange them within a nano-carrier in such a way as to provide this functionality. Another aim of the invention is to adapt the magnetic orientation function to microenvironmental conditions. to prevent the sensitive oscillation function from remaining as two independent properties and these functions within a stepped and / or sequential oscillation architecture The goal is to bring together complementary technical functions. Thus, the external 25 the magnetic field affects the positional behavior of the nano-carrier, nano-carrier It affects the oscillation behavior of micro-environmentally sensitive structures within it and Inter-level access structures for successive reserves of therapeutic active substances an integrated control architecture that regulates the transmission during oscillation phases The aim is to create. 30 Another aim of the invention is to determine the time interval during which the nano-carrier is held in the target region. functional compatibility between the delivery of the therapeutic active substance at different release levels The aim is to enable the creation of a nano-carrier in the target region. 17 during its presence, the different reserves of therapeutic active substances within the carrier it can be used in a controlled manner and the nano-carrier generated in the target region The aim is to utilize its concentration throughout the release process. Another aim of the invention is to detect different releases of different amounts of the same therapeutic active substance. can be kept in compartments and the amounts in question have different oscillations 5 The aim is to enable this to be communicated through behavior. In addition, appropriate in applications different therapeutic active substances in different release chambers transport and the release sequence of the active substances in question and / or different The aim is to be able to release it according to its oscillation characteristics. Another objective of the invention is to customize the oscillation profile to suit different application requirements. The aim is to develop a nano-carrier architecture that allows for its structuring. within the scope of the number of oscillation chambers, their relative positions, and the therapeutic effects they carry. active ingredient amounts, sensitivity to microenvironmental conditions, separating release compartments barrier characteristics, inter-level access characteristics, oscillation delay characteristics and the transition characteristics between the nano-carrier's external environment and the release chambers are 15 by changing different graded and / or sequential oscillation profiles The aim is to enable its creation. Another aim of the invention is to differentiate the basic functions of the nano-carrier system from each other. independent components can only be physically assembled within the same supporting structure. not by introducing them, but by defining the structural and functional 20 components in question. to be realized through an integrated architecture that operates through relationships The aim is to provide magnetic components and therapeutically active substances. release chambers containing reserves, microenvironmental condition-sensitive release regulation structures, selective oscillation barriers, controlled oscillation transition channels, stages inter-level access interfaces, inter-level sequential access management structure, tiered 25 the oscillation control layer and the interstage oscillation retardation barrier positioning of these structures within a defined structural order and Microenvironmental control of the therapeutic active substance through magnetic positional control of nano-carriers. a functional system that connects conditional stepped and / or sequential oscillation control The aim is to create an architectural design. Thus, magnetic orientation, 30 sensitivity to microenvironmental conditions, inter-level access modification, and therapeutic efficacy. Delaying the transfer of substances should not be considered as independent technical features, but rather as the same 18 complementary control functions of the nano-carrier system It can be accomplished. Another aim of the invention is to identify materials that can be used in the production of nano-carrier systems. It is not necessarily dependent on a single chemical composition; however, magnetic orientation, biocompatibility, therapeutic active substance delivery, response to microenvironmental conditions, 5 Regulating inter-level access and controlled incremental and / or sequential oscillation. a system architecture that allows functional regions that perform their functions to be preserved The goal is to integrate different therapeutic active ingredients into the system using different carrier materials. and is designed to be configurable for different application requirements. The ultimate goal of the invention is to create a magnetic 10-cell container that carries the therapeutic active substance. through its components, it is under the influence of an external magnetic field on the target region. can be directed, concentrated around the target area and / or in the target area. a therapeutically active substance that can be retained, respond to microenvironmental conditions, and is structurally present. and / or multiple functionally separated oscillation characteristics 15 that can accommodate more oscillations in the oscillation chamber, occurring in one oscillation stage. access of the microenvironmental environment to the subsequent oscillation stage through change and the relationship between access and the delivery of the therapeutically active substance by controlling through different barrier, interface, transition and delay structures therapeutically an integrated nano- that can release the active ingredient in a gradual and / or sequential manner. to create a carrier system; thus enabling magnetic positional control, microenvironmental 20 selectivity, inter-stage access control, and temporal therapeutic active substance release. The goal is to perform the control within the same technical architecture. Explanation of the Figures Figure 1: Magnetic field-driven stepwise drug delivery system; nano-carrier main the body's external magnetic field generating unit, magnetic field directing element and 25 via a magnetic field concentrating element towards the target tissue region. directing, concentrating around the target tissue region and / or target tissue retention in the region and targeting located on the nano-carrier main body This is a schematic view showing the general arrangement of functional surface binders. Figure 2: Magnetic core carrier 30 located within the nano-carrier main body. the compartment, the magnetic core carrier compartment containing the magnetic special nanoparticles and magnetic nanoparticle fixation matrix, magnetic magnetic core containment layer surrounding the core carrier compartment and nano- 19 structural support of functional areas within the main load-bearing body Schematic cross-section showing the positions of the inner supporting layers relative to each other. It is the appearance. Figure 3: First, second, and third therapeutic agents within the nano-carrier main body. substance release compartments, the first and fifth located within those release compartments the second and third therapeutic active substance reserves are functionally stored in release chambers. Related first, second and third microenvironmental condition-sensitive release regulation their structures, the first, second and third controlled oscillation transition channels, the first, second and third selective oscillation barriers, access interfaces between the first and second stages, sequential access control structure between levels, microenvironmental input channel, 10 staged oscillation control layer and interstage oscillation retardation barrier schematic cross-section showing the structural and functional relationships between them It is the appearance. Figure 4: External view of a stepped drug delivery system guided by a magnetic field. its configuration; a biocompatible outer protective layer surrounding the nano-carrier main body 15 the relative position of the coating layer and the surface stabilization layer and transmitted via a stepped oscillation architecture within the nano-carrier main body controlled transfer of the therapeutic active substance outside the nano-carrier main body. This is a schematic cross-sectional view showing the position of the controlled oscillation outlet aperture. References: 20 1. Magnetic field-guided stepped drug delivery system 2. Nano-carrier main body 3. Magnetic core carrier compartment 4. Magnetic nanoparticles 5. Magnetic nanoparticle fixation matrix 25 6. Magnetic core containment layer 7. Inner support layer 8. First therapeutic active substance release chamber. 9. Primary therapeutic active substance reserve 10. First microenvironmentally sensitive release regulation structure 30 11. First controlled oscillation transition channel 12. First selective oscillation barrier 13. Inter-level access interface 14. Second therapeutic active substance release chamber. 15. Second reserve of therapeutic active substance. 16. Second microenvironmental condition-sensitive emission regulation structure. 17. Second controlled oscillation transition channel 18. Second selective oscillation barrier 5 19. Inter-level access interface 20. Third therapeutic active substance release chamber. 21. Third therapeutic active substance reserve 22. Third microenvironmental condition-sensitive emission regulation structure. 23. Third controlled oscillation transition channel 10 24. Third selective oscillation barrier 25. Inter-level sequential access management structure 26. Microenvironmental input channel 27-stage oscillation control layer 28. Inter-stage oscillation delay barrier 15 29. Biocompatible outer protective coating layer 30. Surface stabilization layer 31. Surface binders with targeting function 32. External magnetic field generating unit 33. Magnetic field guiding element 20 34. Magnetic field concentrating element 35. Target tissue region 36. Controlled oscillation exit opening Description of the Invention: The invention describes the transport of the therapeutic active substance to the target site and the delivery of the therapeutic active substance to the target area. the nano-carrier structure moves towards the target region under the influence of an external magnetic field. directing and increasing the density of nano-carriers around the target region and / or retention of the nano-carrier structure in the target region, microenvironment of the target region physical and / or effects of conditions on the oscillation architecture within the nano-carrier causing a chemical change and structural differences between the therapeutic active substance and the others. and / or controlled, incremental oscillation via functionally separated oscillation stages. and / or guided by a magnetic field that enables its sequential release It is related to the stepped drug release system (1). 21 Magnetic field-guided stepwise drug release system (1), the therapeutic active substance the movement and functionally related oscillation stages nano-carrier main body (2) that enables its creation and nano-carrier main body (2) an external magnetic field generating unit that enables the creation of a magnetic force on it. (32) is based on the functional relationship established between the nano-carrier main body (2); 5 magnetic properties-providing components, reserves of therapeutic active substances, microenvironment condition-responsive release regulatory structures, therapeutic active substance delivery regulating barrier and transition structures, microenvironmental between oscillation stages interfaces that regulate access and controlled transitions between those levels an integrated load-bearing architecture incorporating delay structures 10 It creates. The stepwise structure created within the nano-carrier main body (2) and / or sequential release architecture, controlled release from therapeutic active substance reserves. for the transfer of the therapeutic active substance outside the nano-carrier main body (2) It is functionally associated with the controlled oscillation output opening (36). Controlled Release opening (36), controlled release transition from the relevant therapeutic active substance reserve 15 the therapeutic active substance transferred through the channel out of the nano-carrier main body (2) It is being structured in a way that will allow for controlled and phased transfer. It constitutes the final matter transfer region of the oscillation architecture. Nano-carrier main body (2), magnetic with therapeutic active substance delivery function. 20 It is structured. The magnetic core carrier within the nano-carrier main body (2) compartment (3) is located. Magnetic core carrier compartment (3), nano-carrier main The guide, positioner, under the influence of an external magnetic field on the body (2), Magnetic that enables the creation of a concentrating and / or holding magnetic effect. It forms a defined transport site for special nanoparticles (4). 25 Magnetic nanoparticles (4), external magnetic field generating unit (32) magnetic properties that can interact with the magnetic field generated by They are made of materials. Magnetic nanoparticles (4), iron oxide-based magnetic nanoparticles and / or biological transport systems It can be created from other suitable magnetic nanostructures. 30 and the invention is not limited to a specific magnetic material composition. Magnetic special nanoparticles (4) components in nano-carrier main body (2) Quantity, distribution, density and relative position of nano-carrier main body (2) 22 in a way that is suitable for creating the targeted magnetic interaction It can be edited. Magnetic nanoparticle fixation in magnetic core carrier compartment (3) The magnetic nanoparticle fixation matrix (5) is available. special nanoparticles (4) magnetic core carrier compartment of components (3) 5 to be held in the determined position inside the nano-carrier main body (2) the preservation of their distributions and unwanted outflow of nano-carrier main body (2) This ensures that their separation is limited. Magnetic nanoparticle fixation. The matrix (5) contains magnetic nanoparticles (4) components dispersed within it, 10 biocompatible materials that can be kept embedded, attached and / or physically confined. It can be structured in the form of a carrier matrix. Magnetic core containment layer around the magnetic core carrier compartment (3) (6) is located. Magnetic core containment layer (6), magnetic core carrier Release of the therapeutic active substance into the nano-carrier main body (2) through compartment (3) It creates a structural boundary between the architectures; 15 with magnetic properties direct and uncontrolled relationship between nanoparticles (4) and therapeutic active substance reserves limiting the interaction and the integrity of the magnetic core carrier compartment (3) It contributes to the protection of the magnetic core containment layer (6), magnetic will not eliminate the effect of the field on the magnetically charged nanoparticles (4) and will maintain the magnetic orientation of the nano-carrier main body (2) component 20 It is structured in this way. Regarding the release of therapeutic active substance with magnetic core containment layer (6) The internal support layer (7) is located between the functional regions. Internal support layer (7), magnetic core structure within nano-carrier main body (2), therapeutic active substance release chambers, selective release barriers, controlled 25 oscillation transition channels and inter-stage access structures relative to each other a supporting and separating structure that contributes to the preservation of their designated positions It brings. The inner carrier support layer (7) inside the nano-carrier main body (2) will limit unwanted direct transfer of substances between different functional regions and the delivery of the therapeutic active substance through defined transit routes 30 It can be arranged in a way that will provide support. The therapeutic active substance is released in a single homogeneous release within the nano-carrier main body (2). not kept within its volume; firstly, structurally and / or functionally separated from each other 23 therapeutic active substance release compartment (8), second therapeutic active substance release compartment (14) and the third therapeutic active substance is distributed in the release chamber (20). First therapeutic active substance release chamber (8), second therapeutic active substance release chamber compartment (14) and third therapeutic active substance release compartment (20), relative to each other nano-5 will create a defined oscillation sequence and an access relationship between stages It is located inside the carrier main body (2). First therapeutic active substance release chamber (8), second therapeutic active substance release chamber compartment (14) and third therapeutic active substance release compartment (20) layered, radial, sequential, regional, surrounding and / or connected by defined transit routes They can be formed by geometric arrangements. Of these geometric arrangements, 10 The structural and functional separation of the oscillation chambers is maintained independently; therapeutic All reserves of active substances must be simultaneously and under the same microenvironmental conditions. Instead of being released uncontrollably, separate oscillation stages is being created. The first therapeutic active substance is contained in the first therapeutic active substance release chamber (8) 15 There is a reserve (9). The first therapeutic active substance reserve (9) is the nano-carrier main When the body (2) encounters the targeted microenvironmental condition, in the first oscillation stage the entire amount of therapeutic active substance intended to be released or the specified amount It includes the first therapeutic active substance reserve (9), first therapeutic active Physically confined, dissolved, dispersed within the substance release compartment (8), 20 maintained in physical and / or chemical interaction with the carrier material and / or suitable It can be found preserved within a carrier phase. The first therapeutic active substance release compartment (8) is functionally related to the first There is a microenvironmental condition-sensitive release regulation structure (10). First microenvironmentally sensitive release regulation structure (10), nano-carrier main body (2) 25 physical and / or has a structure whose chemical behavior can change. It is sensitive to the first microenvironmental condition. release regulation structure (10), in particular to respond to pH change While it is possible to create it, temperature, redox conditions, enzymatic activity and / or target There are 30 other differentiable tissue region (35) and non-target biological environment It can also be configured to respond to microenvironmental variables. The first microenvironmental condition-sensitive release regulation structure (10) Changes in permeability, swelling, and dissolution occurring depending on microenvironmental conditions. 24 bond separation, structural opening, physical integrity change and / or therapeutic active substance Change in interaction between the carrier structure and the primary therapeutic active substance reserve (9) It alters the release behavior of the component. This alteration affects the first therapeutic component. direct uncontrolled release of the active substance reserve (9) component instead, transition structures associated with the first therapeutic active substance release compartment (8) 5 It is used in a way that allows it to be transferred through. First controlled release transition channel (11), first therapeutic active substance reserve (9) the first therapeutic active substance release chamber (8) of its component is released in a controlled manner. It is a defined passage that enables the transfer. First controlled oscillation passage channel (11) the cross-sectional area, length, geometry, porosity, permeability and / or therapeutic properties of its component 10 The first therapeutic agent is modified by altering the resistance it creates to the delivery of the active substance. The release rate and / or release duration of the substance reserve (9) component can be regulated. First selective release barrier associated with the first therapeutic active substance release compartment (8) (12), targeted microenvironment of the first therapeutic active substance reserve (9) component 15 before the conditions are met, outside the first therapeutic active substance release chamber (8) It limits the uncontrolled transfer. The first selective oscillation barrier (12), direct and / or with the first microenvironmental condition sensitive release regulation structure (10) It is in an indirect functional relationship. It is sensitive to the first microenvironmental condition. Physical and / or chemical events occurring on the release regulation structure (10) The change affects the permeability of the first selective oscillation barrier (12) component, the open state 20 and / or the transfer resistance it creates against the delivery of the therapeutic active substance It can be changed. The biological microenvironmental environment outside the nano-carrier main body (2) and the nano-carrier main Controlled linkage between the stepped oscillation architecture inside the body (2) The microenvironmental environment is provided through the inlet channel (26). Microenvironmental environment 25 inlet channel (26), liquid medium around nano-carrier main body (2), ions, physical or chemical agents representing molecules and / or microenvironmental conditions access to the relevant oscillation regulation structures within the nano-carrier main body (2) It creates a defined entry path that provides access. The microenvironmental environment entry channel (26) is the first therapeutic effective channel of the external microenvironmental environment. substance release chamber (8), second therapeutic active substance release chamber (14) and third all components of the therapeutic active substance release compartment (20) at the same time and at the same time It is structured in such a way that it does not necessitate reaching it through transition resistance. The progression of the microenvironmental environment within the nano-carrier main body (2), oscillation the relative positions of the stages, access interfaces between the stages, selective oscillation barriers, sequential access arrangement structure between levels (25) and between levels It is subject to the access relationship determined by the oscillation delay barrier (28). The first 5 of the microenvironmental conditions accessed through the microenvironmental environment inlet channel (26) microenvironmental condition sensitive release regulation structure (10) on physical and / or first selective release barrier (12) as a result of chemical change The transit behavior of the component is altered and the first therapeutic active substance reserve (9), It can be transmitted in a controlled manner through the first controlled oscillation transition channel (11). It is coming. This structure constitutes the first oscillation stage. 10 First therapeutic active substance release chamber (8) and second therapeutic active substance release chamber There is an inter-level access interface (13) between compartments (14). First inter-level access interface (13), only first therapeutic active substance release a physical boundary between compartment (8) and the second therapeutic active substance release compartment (14) not forming; physical and / or chemical 15 occurring in the first release stage the ability of the microenvironment to access the second oscillation stage of the change It creates a functional transition zone that provides Permeability and physical integrity of the first-level access interface (13) component, resistance to openness and / or microenvironmental transition; firstly microenvironmentally sensitive oscillation regulation structure (10), first selective oscillation 20 inside the barrier (12) and / or the first therapeutic active substance release chamber (8) It is associated with the physical and / or chemical change that occurs. First Second therapeutic active substance release via inter-level access interface (13) Microenvironmental access created in the direction of compartment (14), sequential between levels Access regulation structure (25) defined access between oscillation levels 25 It is connected to the sequence. Inter-level sequential access arrangement structure (25), first physical and / or chemical change associated with the therapeutic active substance release compartment (8) microenvironmental aspects of the second therapeutic active substance release chamber (14) firstly, in a way that will bring about a change in the accessibility status It is functionally associated with the inter-level access interface (13). The aforementioned 30 Change in accessibility status of the second therapeutic active substance reserve (15) component This does not mean directly transitioning to the active oscillation state; it means between stages. release delay barrier (28), which becomes accessible in terms of microenvironmental environment 26 second therapeutic active substance release chamber (14) and second therapeutic active substance reservoir (15) an additional and controllable transition resistance between the effective release of component. This creates the physical effects that occur in the first oscillation stage. and / or chemical change, microenvironmental accessibility of the second release stage the first control event that changes its state; interstage oscillation delay barrier 5 The transition organized via (28) is the second therapeutic active substance reserve (15) component. Second control affecting the onset of oscillation, oscillation speed and / or oscillation duration. This creates the event. These two control events are structurally and functionally... The activation of the first release stage, the second therapeutic phase, thanks to their separation The active substance release compartment (14) component is accessible in terms of microenvironment. becoming effective and the second therapeutic active substance reserve (15) component's effective release The transition to this state is being removed from the realm of events that necessarily occur simultaneously; The events in question are interstages created within the nano-carrier main body (2). Access and delay architectures that are related but separate control phases. It is organized as follows: 15 The second therapeutic active substance is released into the second therapeutic active substance release chamber (14). There is a reserve (15). The second therapeutic active substance reserve (15) is the first therapeutic active substance reserve (9) with different amounts of the same therapeutic active substance and / or It may contain a concentration or consist of a different therapeutic active substance. It can be delivered. The second therapeutic active substance release compartment (14), the second therapeutic active substance 20 substance reserve (15) component simultaneously with the first therapeutic active substance reserve (9) and structural and / or functional factors that would prevent its release with the same oscillation characteristic It creates the distinction. Second microenvironmental condition associated with the second therapeutic active substance release chamber (14) responsive release regulation structure (16), secondary therapeutic active substance reserve (15) 25 It regulates the oscillation behavior of its component depending on microenvironmental conditions. The second microenvironmental condition-sensitive release regulation structure (16), the first microenvironmental condition-sensitive oscillation regulation structure (10) with the same or different physical and / or It can be formed in chemical composition; with different reaction thresholds, reaction rates, and permeability. change, swelling behavior, dissolution behavior, bond separation property and / or 30 It can exhibit structural change characteristics. Second controlled release transition channel (17), second therapeutic active substance reserve (15) Controlled release of the component from the second therapeutic active substance release chamber (14) 27 It is a defined transition path that enables the transmission in this manner. Second controlled oscillation transition. channel (17), cross-sectional area different from the first controlled oscillation transition channel (11) component, in a way that will exhibit length, permeability, porosity and / or resistance to penetration can be created; thus, the first therapeutic active substance reserve (9) and the second therapeutic Therapeutic active substance transfer for different active substance reserves (15) 5 Characteristics can be created. The second selective release barrier (18) is a component of the second therapeutic active substance reserve (15). uncontrolled transfer of the second therapeutic active substance outside the release chamber (14) It limits. The second selective release barrier (18) is the second microenvironmental condition. It is functionally related to the sensitive oscillation regulation structure (16) and the second 10 microenvironmental condition sensitive oscillation regulation structure (16) occurring on against the transfer of therapeutic active substance due to physical and / or chemical change. The resistance it creates can vary. The change occurring in the first release phase is due to the second therapeutic active ingredient. providing access to the microenvironmental environment on the side of the release chamber (14), second therapeutic 15 direct and uncontrolled release of the active substance reserve (15) component It does not necessarily produce the result. Inter-stage oscillation delay. barrier (28), access between first levels provided via interface (13) effective second therapeutic active substance reserve (15) component with microenvironmental access This creates an additional resistance between the oscillations. 20 Interstage oscillation delay barrier (28); permeability, thickness, pore structure, dissolution behavior, swelling properties, response to microenvironmental conditions and / or occurrences the transition behavior between levels through the diffusion resistance it introduces It regulates this. Thus, the structural change in the first oscillation stage is replicated in the second. By providing access to the microenvironmental environment at the release stage, the second therapeutic effect is 25. The start of release of the material reserve (15) component can be separated from each other; second the first therapeutic active substance reserve (9) of the component of the therapeutic active substance reserve (15) Simultaneous and uncontrolled ejaculation is restricted. The second therapeutic active substance release chamber (14) and the third therapeutic active substance There is an inter-stage access interface (19) between the oscillation compartment (20). 30 Second inter-stage access interface (19), second therapeutic active substance release chamber (14) third therapeutic effect of physical and / or chemical change occurring within 28 can change the access of the microenvironment to the substance release compartment (20) It is a functional transition zone that provides Permeability and physical integrity of the second-level inter-access interface (19) component, resistance to openness and / or microenvironmental transition; second microenvironmentally sensitive release regulation structure (16), second selective release barrier 5 (18) and / or occurring in the second therapeutic active substance release chamber (14) It is associated with physical and / or chemical change. Second-stage access. via interface (19) towards the third therapeutic active substance release chamber (20) The microenvironmental access created, the sequential access arrangement structure between levels (25) as a continuation of the defined access sequence between the oscillation stages 10 is organized. Inter-level sequential access regulation structure (25), second therapeutic The third physical and / or chemical change associated with the active substance release compartment (14) Microenvironmental accessibility in terms of therapeutic active substance release compartment (20) in a way that will bring about a change in the situation between the second levels It is functionally associated with the access interface (19). This accessibility 15 change of condition, direct effect of the third therapeutic active substance reserve (21) component It does not cause it to enter the oscillation state; oscillation delay between stages. the third therapeutic barrier (28) which becomes accessible in terms of microenvironmental environment active substance release chamber (20) and third therapeutic active substance reserve (21) An additional and controllable transition resistance occurs between the effective release of the component. 20 This brings about physical and / or adverse effects occurring in the second oscillation stage. microenvironmental accessibility status of the third release stage of chemical change while creating a control event that modifies, the third therapeutic active substance reserve (21) oscillation start, oscillation speed and / or oscillation duration of component between stages Release delay barrier (28), third microenvironmental condition sensitive release regulation 25 structure (22), third selective oscillation barrier (24) and third controlled oscillation transition channel (23) is also regulated by. In this way, the second oscillation stage activation of the third therapeutic active substance release compartment (20) component making the microenvironment accessible and the third therapeutic effect The transition of the substance reserve (21) component to the effective release state is functional with each other 30 related but structurally separate control stages is being carried out. 29 The third therapeutic active substance is released into the third therapeutic active substance release chamber (20). There is a reserve of therapeutic active substance (21). The third therapeutic active substance reserve (21) is the first. with therapeutic active substance reserve (9) and / or second therapeutic active substance reserve (15) They may contain the same therapeutic active ingredient in different amounts and / or concentrations, or It may consist of a different therapeutic active ingredient. The third therapeutic active ingredient is 5. substance release compartment (20), the previous component of the third therapeutic active substance reserve (21) different release initiation conditions, transfer rates and / or from therapeutic active substance reserves It is structured in such a way as to allow its release under a period of time. Third microenvironmental associated with the third therapeutic active substance release chamber (20) Condition-sensitive release regulation structure (22), third therapeutic active substance reserve (21) 10 It regulates the oscillation behavior of its component depending on microenvironmental conditions. Third microenvironmental condition-sensitive release regulation structure (22), to the first microenvironmental condition sensitive oscillation regulation structure (10) and second microenvironmental condition sensitive oscillation different response threshold, response rate, permeability change from the components of the regulatory structure (16), dissolution behavior, swelling properties, bond separation characteristics and / or physical integrity 15 It can show the change. Third controlled release transition channel (23), third therapeutic active substance reserve (21) Controlled release of the component from the third therapeutic active substance release chamber (20) It is a defined transition path that enables the transmission in this manner. Third controlled oscillation transition. The cross-sectional area, length, geometry, permeability, and porosity of the channel (23) component 20 and / or transition resistance, targeted release for the third therapeutic active substance reserve (21) It can be customized according to its characteristics. The third selective release barrier (24) is a component of the third therapeutic active substance reserve (21). uncontrolled out of the third therapeutic active substance release chamber (20) It restricts the transfer. The third selective oscillation barrier (24), third 25 functional relationship with the microenvironmentally sensitive release regulation structure (22) and third microenvironmental condition sensitive release regulation structure (22) therapeutic efficacy depending on the physical and / or chemical changes occurring on it The resistance it creates to substance transfer can vary. First therapeutic active substance release chamber (8), second therapeutic active substance release chamber 30 between compartment (14) and third therapeutic active substance release compartment (20) the microenvironmental access sequence and the functional dependence between emission levels inter-level sequential access regulation structure that enables its creation (25) It is located. Inter-level sequential access regulation structure (25), an oscillation the subsequent release of physical and / or chemical changes occurring at this stage direct or indirect access of the microenvironment to the level It creates a structural relationship that it can change. Inter-level sequential access regulation structure (25), inter-level access intermediate 5 functionally with face (13) and second level access interface (19) associated with; first therapeutic active substance release compartment (8), second therapeutic active substance release compartment (14) and third therapeutic active substance release compartment (20) not as completely independent oscillation volumes of its components, as in the previous physical and / or chemical change in the release phase followed by release 10 working within a sequential architecture where the level affects the access condition It provides. Inter-level sequential access arrangement structure (25); permeable intermediate zone, physical transition channel, microenvironmentally sensitive transition zone, soluble structure, swellable structure, Tracking 15 depending on the change in the porous transition zone and / or an oscillation stage. structural arrangements that can alter microenvironmental access to the emitting stage It can be created. Inter-level sequential access arrangement structure (25) the physical form of its component preserves the structural relationship between the oscillation stages With this registration, it can be arranged according to different nano-carrier geometries. Inter-level sequential access regulation structure (25) and inter-level oscillation 20 Delay barrier (28) complementary but different technical functions It fulfills the inter-level sequential access management structure (25), previous the change in the oscillation stage to the next oscillation stage in the microenvironment while enabling it to change its access, the interstage oscillation delay barrier (28), The issue is the direct and uncontrolled access of the subsequent reserve of therapeutic active substances. This structural distinction limits its transformation into an emptying process. "access to the next stage" and "effectiveness of the subsequent therapeutic active substance reserve" "The onset of release" is transformed into separate control phases. The stepped oscillation control layer (27) is the first in the nano-carrier main body (2). therapeutic active substance release compartment (8), second therapeutic active substance release compartment 30 (14) and the difference created between the third therapeutic active substance release compartment (20) preserving the structural separation of the oscillation stages and the oscillation in question the general therapeutic active substance delivery characteristics of their levels relative to each other 31 It is an integrated control structure that contributes to its regulation. Stepwise oscillation control. layer (27), the relevant access and passage routes of the microenvironmental environment regulation of interaction with release stages, delivery of therapeutic active substance the relevant controlled oscillation transition channels are used to carry out different oscillations different transmission resistances and oscillation characteristics between the stages 5 in a way that will contribute to its creation within the nano-carrier main body (2) It is positioned. The stepped oscillation control layer (27) component has different oscillations. thickness, permeability, porosity, and material composition in the regions related to their layers, dissolution behavior, swelling behavior, diffusion resistance and / or microenvironmental conditions The given physical and / or chemical response can be varied; thus, the first therapeutic 10 active substance release compartment (8), second therapeutic active substance release compartment (14) and between the third therapeutic active substance release chamber (20) there is only one physical not segmentation, but different general transfer characteristics a functional oscillation control architecture that serves to create It can be brought. Inter-level sequential access regulation structure (25), previous oscillation 15 depending on the physical and / or chemical change occurring at that stage Modifying the microenvironmental accessibility status of the emission stage while performing the inter-level access function; inter-level oscillation retardation barrier (28), in the subsequent oscillation stage that becomes accessible 20 It performs the delay function. The stepped oscillation control layer (27) without directly repeating the access and delay functions in question, different the general transfer behavior of therapeutic active substance release compartments to each other according to the arrangement and the oscillation of the compartments in question separated from each other. integrative control function that contributes to the preservation of its characteristics 25 Thus, the sequential access regulation structure between levels (25), stepped oscillation control layer (27) and interstage oscillation retardation barrier (28) are not elements that repeat the same technical task; they are oscillations that follow each other in sequence. Changing the microenvironmental accessibility status of the stage, different emissions Regulation of general transfer behaviors of the levels and accessible tracking 30 transition of the therapeutic active substance reserve in the release phase to effective release They are distinguished from each other by the creation of additional resistance to transmission and by the fact that they are different from each other. It creates complementary technical functions. 32 Biocompatible outer protective coating layer around the nano-carrier main body (2) (29) is located. Biocompatible outer protective coating layer (29), nano-carrier main It creates a biocompatible interface between the body (2) and the biological environment, nano- uncontrolled direct contact of the functional components inside the carrier main body (2) with the external environment limiting contact and preserving the integrity of the nano-carrier main body (2) 5 It contributes. The biocompatible outer protective coating layer (29) is microenvironmental The components of the medium inlet channel (26) and controlled oscillation outlet opening (36) are material It is configured in a way that will not interfere with transfer functions. biocompatible outer protective coating layer (29) and / or biocompatible outer surface stabilization layer (30) integrated with protective coating layer (29) 10 It has a surface stabilization layer (30), nano-carrier main body (2) the undesirable clumping of its components together within the biological environment limiting, nano-carrier main body (2) contributes to the regulation of surface properties It provides and supports the dispersion stability of the nano-carrier structure. Targeting function surface binders (31) on the nano-carrier main body (2) 15 can be found. Targeting functional surface binders (31), target tissue region (35) can bind to and / or selectively interact with biological structures associated with those structures. It can be composed of surface components that can interact. Targeting Functional surface binders (31), biological targeting in addition to magnetic orientation It provides the feature of a stepped drug release system guided by a magnetic field (1) 20 It is not a necessary element of the component's magnetic orientation function. External magnetic field generating unit (32), inside nano-carrier main body (2) Magnetic effect occurs on the magnetic nanoparticles (4) found. It creates a magnetic field that can be generated. External magnetic field generating unit (32), permanent magnet, electromagnetic field generating device and / or controllable 25 It can be configured in the form of a field generation system that generates a magnetic field. Magnetic field guiding element associated with the external magnetic field generating unit (32) (33), the arrangement of the generated magnetic field towards the target tissue region (35) Magnetic field guiding element (33) provides magnetic field lines. and / or magnetic field gradient between the target tissue region (35) and the nano-carrier main body 30 It contributes to the arrangement according to the positional relationship between (2). Magnetic field concentrating element (34), external magnetic field generating unit (32) magnetic field generated by around the target tissue region (35) 33 intensification and / or magnetic field towards the target tissue region (35) It enables the gradient to be increased. External magnetic field generating unit (32), magnetic field guiding element (33) and magnetic field concentrating element (34) The relationship between the nano-carrier main body (2) and the target tissue region (35) is in the direction of the nano-carrier main body (2). It is designed to generate sufficient magnetic effect. 5 The target tissue region (35) is where the therapeutic active substance is delivered in a controlled manner and magnetic orientation of the nano-carrier main body (2) component and / or Target tissue region (35) is the biological region that is intended to be retained. The target tissue region is primarily the tumor tissue. different biological tissues where therapeutic active substances are intended to be administered It can include the pH, temperature, redox in the microenvironment of the target tissue region (35). conditions, enzymatic activity and / or other physical or chemical properties of nano-carriers microenvironmental condition-sensitive oscillation regulation structures within the main body (2) It can be used under control. Transferred via the stepwise oscillation architecture within the nano-carrier main body (2) Transfer of the therapeutic active substance outside the nano-carrier main body (2) controlled release 15 Controlled oscillation is achieved through the outlet opening (36). The outlet opening (36) a single opening, multiple micro-openings, porous exit zone and / or therapeutic effect It can be designed as a permeable exit interface that allows material transfer. The cross-sectional area, number, permeability and nano- of the controlled oscillation outlet opening (36) component The delivery of the therapeutically active substance to the target location on the carrier main body (2) 20 It can be adjusted according to behavior. magnetic field guided step-in drug delivery system (1) In the study setup carried out, the nano-carrier main body (2) is placed in the biological environment. external magnetic field generating unit while moving in the direction of target tissue region (35) It interacts with the magnetic field generated by (32). Magnetic field 25 Targeted by the guiding element (33) and magnetic field concentrating element (34) Magnetic field arranged in the direction of tissue region (35), magnetic nanoparticles (4) creates a magnetic effect on the nano-carrier main body (2) component. to direct towards the target tissue region (35), around the target tissue region (35) increasing its density and / or keeping it around the target tissue region (35) 30 It provides an opportunity. Nano-carrier main body (2) interacts with the microenvironment of the target tissue region (35) When it enters, the microenvironmental environment is introduced through the input channel (26) into a stepped oscillation architecture. 34 Microenvironmental access occurs. The first microenvironmental condition of the microenvironmental physical and / or effects it produces on the condition-sensitive oscillation regulation structure (10) transition of the first selective release barrier (12) component as a result of chemical change behavior is being modified and the first therapeutic active substance reserve (9), first controlled The oscillation is transmitted in a controlled manner through the oscillation channel (11). 5 The physical and / or chemical change that occurs in the first stage of oscillation is the first inter-level access interface (13) and inter-level sequential access management structure (25) via the microenvironmental side of the second therapeutic active substance release chamber (14). It changes the medium access. Inter-stage oscillation delay barrier (28), word The subject is microenvironmental access to the second therapeutic active substance reserve (15) component 10 It limits the possibility of it turning into a direct and uncontrolled discharge. Second microenvironmental condition sensitive oscillation regulation structure (16) occurring on physical and / or chemical change, transition of the second selective release barrier (18) component. changing its behavior and second therapeutic active substance reserve (15), second controlled The oscillation is transmitted in a controlled manner through the transition channel (17). 15 The physical and / or chemical change that occurs in the second release stage, the second inter-level access interface (19) and inter-level sequential access management structure via (25) to the third therapeutic active substance release chamber (20) side It alters the accessibility of the microenvironment. Inter-stage oscillation delay. barrier (28), the second therapeutic active component of the third therapeutic active substance reserve (21) 20 It limits the depletion of the material reserve (15) simultaneously and uncontrollably. The third microenvironmental condition-sensitive release regulation structure (22) occurs on the resulting physical and / or chemical change, the third selective release barrier (24) component altering the transition behavior and the third therapeutic active substance reserve (21), third The controlled oscillation is transmitted in a controlled manner through the transition channel (23). 25 First therapeutic active substance reserve (9), second therapeutic active substance reserve (15) and Therapeutic efficacy carried out from the components of the third therapeutic active substance reserve (21) Substance transfer, controlled release output via relevant controlled release transition channels. The sound is transmitted in the direction of the aperture (36) and the controlled oscillation is transmitted through the aperture (36) to the target The tissue region (35) is transferred to the surrounding area. The stepped release control layer (27), word 30 The subject is the structural separation of delivery pathways, the delivery of therapeutically active substances. carried out via designated transition paths and different oscillation levels This contributes to maintaining distinct oscillation characteristics. 35 The stepped oscillation control layer (27) is separated from each other within the nano-carrier main body (2). will be functionally related to the separated oscillation stages and the oscillation in question direct and uncontrolled transfer of therapeutic active substance between levels It can be organized as a structural control zone that extends in a way that will limit its boundaries. Step oscillation control layer (27), sequential access regulation structure between steps 5 (25) and working together with the interstage oscillation delay barrier (28) Microenvironmental access and the delivery of therapeutically active substances are kept separate, but Contributes to maintaining functionally related control states It provides. The gradual and / or sequential oscillation behavior produced in the invention is only in the first 10 therapeutic active substance reserve (9), second therapeutic active substance reserve (15) and third the therapeutic active substance reserve (21) components within the nano-carrier main body (2) It is not based on being in different physical locations. The first microenvironmental condition... sensitive oscillation regulation structure (10), oscillation sensitive to the second microenvironmental condition regulation structure (16) and third microenvironmental condition sensitive release regulation structure 15 (22) Microenvironmental response behaviors of the components; first selective release barrier (12), second selective oscillation barrier (18) and third selective oscillation barrier (24) components Transition characteristics; first controlled oscillation transition channel (11), second controlled oscillation transition The transmission resistances of the channel (17) and the third controlled oscillation transition channel (23) components; first level access interface (13) and second level access interface (19) 20 sequential access between levels with microenvironmental access behaviors of its components regulation structure (25), stepped oscillation control layer (27) and interstage oscillation The structural and functional relationship established between the delay barrier (28) is gradually established together. and / or creates a sequential oscillation architecture. First therapeutic active substance release chamber (8), second therapeutic active substance release chamber 25 compartment (14) and third therapeutic active substance release compartment (20) surround each other. layered regions, regions arranged radially relative to each other, nano-carrier main Separate regional volumes and / or defined transitions within the body (2) They can be formed in the form of oscillation volumes connected to each other by pathways. Oscillation Even if the geometric layout of the compartments is changed, the first-level inter-level access interface remains 30. (13), second level inter-level access interface (19), inter-level sequential access by the regulatory structure (25) and the interstage oscillation delay barrier (28) The established inter-level access and delay relationship is maintained. 36 First therapeutic active substance reserve (9), second therapeutic active substance reserve (15) and third therapeutic active substance reserve (21), the same therapeutic active substance from each other It may include different quantities and / or concentrations. In this regulation, the first the reserve of therapeutic active substance (9) the first controlled transfer of therapeutic active substance, second the reserve of therapeutic active substance (15) followed by the transfer of therapeutic active substance and third 5 the reserve of therapeutic active substance (21) subsequent transfer of therapeutic active substance It can be arranged in such a way as to provide. The first therapeutic active substance reserve (9), second therapeutic active substance reserve (15) and third therapeutic active substance reserve (21) They can also be composed of different therapeutically active substances; thus 10 different therapeutic active substances in a controlled manner according to the determined release sequence It is possible to transfer it. The first microenvironmental condition-sensitive release regulation structure (10), the second microenvironmental condition-sensitive release regulation structure (16) and third microenvironmental condition-sensitive oscillation regulation structure (22), at different response thresholds to the same microenvironmental variable and / or can be configured to respond at different response speeds, as well as in 15 different ways. It can also be configured to respond to microenvironmental variables. In this way The distinction between oscillation stages is due only to a time-dependent passive delay. not resistant; microenvironmental where nano-carrier main body (2) component is located by physical and / or chemical access relationships between conditions and levels is determined. 20 Interstage oscillation retardation barrier (28) component with different oscillation stages Related regions do not necessarily have to have the same physical and / or chemical properties. First therapeutic active substance release compartment (8) and second therapeutic active substance release compartment (14) delay behavior between the second therapeutic active substance release compartment (14) delay behavior between the third therapeutic active substance release compartment (20) 25 It can be differentiated. This differentiation is done through the oscillation delay barrier between stages. (28) Different thickness, permeability, porosity, material in the relevant regions of the component. composition, dissolution time, swelling behavior and / or response to microenvironmental conditions This can be achieved by creating it. First controlled oscillation transition channel (11), second controlled oscillation transition channel (17) and 30 The third controlled oscillation transition channel (23) has different geometric and physical characteristics. They can be created with these features. The cross-section of these controlled oscillation transition channels area, length, connection type, permeability, porosity and / or therapeutic efficacy 37 by differentiating the resistance it creates against substance transfer for each oscillation stage different therapeutic active substance delivery rates and / or release durations occur It can be brought. First selective oscillation barrier (12), second selective oscillation barrier (18) and third selective oscillation barriers (24) differ from each other in material, thickness, permeability and / or 5 They can be formulated in a way that will have microenvironmental response characteristics. Thus targeted release initiation condition for each therapeutic active substance release chamber and The characteristics of therapeutic active substance delivery can be regulated separately. The first therapeutic active substance release chamber (8), the second described within the scope of the invention therapeutic active substance release compartment (14) and third therapeutic active substance release compartment 10 compartment (20), technical working principle of the staged and / or sequential oscillation architecture The three oscillations that explain this form a stepped structure. However, the word The working principle of this subject is not limited to a specific number of oscillation stages, and most at least two structurally and / or functionally separated therapeutic active substance release chambers It can be applied between them. More than two 15 nano-carrier main bodies (2) inside. If a therapeutic active substance release chamber is present, successive releases sequential access between levels with relevant inter-level access interfaces Access regulation relationship implemented by the access regulation structure (25) and Additional transition is achieved by the interstage oscillation delay barrier (28). The relationship for creating resistance can be maintained. Thus, the number of oscillation stages is 20. Even if modified, the physical and / or chemical effects that occurred in the previous release phase will remain the same. microenvironmental accessibility status of the subsequent oscillation stage of the change therapeutic efficacy in the subsequent release phase that changes and becomes accessible The fundamental principle is that the transition of the substance reserve to effective release is further regulated. The control relationship between the levels is maintained. 25 Nano-carrier main body (2), made of biocompatible polymeric materials, lipid-based carrier from materials, inorganic carrier materials, organic-inorganic composites It can be made from various materials and / or combinations thereof. Nano-carrier main body (2) material; magnetic nanoparticles (4) transport of components, preservation of reserves of therapeutic active substances, 30 the creation of separated oscillation chambers and microenvironmental conditions Suitable for integrating sensitive oscillation regulation structures with nano-carrier architecture. It is selected in such a way as to be. 38 The first microenvironmental condition-sensitive release regulation structure (10), the second microenvironmental condition-sensitive release regulation structure (16) and third microenvironmental condition-sensitive The release regulation structure (22) is physical depending on the targeted microenvironmental condition. and / or biocompatible polymeric structures with alterable chemical behavior, hydrogel-based structures, decomposable bond structures, soluble structures, swellable structures, permeability 5 They can be made up of variable structures and / or combinations thereof. The invention is based on a specific type of polymer, a specific binder chemistry, a specific pH value, or It is not limited to a specific therapeutic active ingredient. Size, quantity and nano-carrier main components of magnetic nanoparticles (4) distribution within the body (2), external magnetic 10 of the nano-carrier main body (2) component under the magnetic field generated by the field generating unit (32) necessary for being able to be directed and kept around the target tissue region (35) It can be arranged according to magnetic behavior. Nano-carrier main body (2) component size, geometry, surface properties, biocompatible outer protective coating layer (29), surface stabilization layer (30) and surface binders with targeting function (31) 15 The properties of its components also depend on the targeted biological environment and the therapeutic application. It can be edited. Magnetic field-guided stepped drug delivery system (1) within magnetic field positional control, microenvironmentally sensitive activation, and gradual therapeutic efficacy. Substance release involves the addition of independent functions to the same nano-carrier 20 not in the form of, but control stages structurally and functionally related to each other It is carried out in this way. External magnetic field generation unit (32), magnetic field orientation element (33) and magnetic field concentration element (34) nano- positional of carrier main body (2) component in terms of target tissue region (35) while regulating its behavior; microenvironmental input channel (26), first microenvironmental 25 Condition-sensitive oscillation regulation structure (10), second microenvironmental condition-sensitive oscillation regulation structure (16), third microenvironmental condition sensitive release regulation structure (22), first level access interface (13), second level access interface (19), sequential access regulation structure between levels (25), stepped swing control layer (27) and interstitial release delay barrier (28) therapeutic active substance 30 It regulates the temporal and gradual behavior of its transmission. Thanks to this structural integrity, the nano-carrier main body (2) target tissue region (35) nano- 39 all of the therapeutic active substance reserves contained within the carrier main body (2) Simultaneous release is restricted. First therapeutic active substance reserve. (9), second therapeutic active substance reserve (15) and third therapeutic active substance reserve (21) It is used in a controlled manner in separate oscillation stages; previous Physical and / or chemical changes occurring during the release phase followed by 5 altering microenvironmental access to the oscillation stage and between stages release delay barrier (28) subsequent access to the therapeutic active substance It limits the uncontrolled depletion of the reserve. Magnetic field-guided stepwise drug delivery system (1), magnetic positional The release of the therapeutically active substance dependent on microenvironmental conditions through control is only possible within the same 10 not based on being together within the system; nano-carrier main body (2) containing therapeutic active substances that are structurally and / or functionally separated from each other oscillation chambers and the microenvironmental conditions associated with those oscillation chambers sensitive oscillation regulation structures, selective oscillation barriers, controlled oscillation transitions channels, inter-level access interfaces, inter-level sequential access management 15 structure (25), microenvironmental environment input channel (26), stepped oscillation control layer (27) and the defined structural created between the oscillation retardation barrier (28) between the stages and operates through a functional relationship. This relationship is in an oscillation phase. the subsequent release stage of the physical and / or chemical change that occurs changing the microenvironmental accessibility status and making it accessible for the following 20 years the transition of the therapeutic active substance reserve in the release phase to effective release also by enabling the regulation of the transfer of therapeutic active substances to each other controlled and / or sequential via functionally correlated oscillation stages an integrated nano-carrier architecture that enables this to be realized It brings. 25 The physical phenomenon occurring in an oscillation phase in the technical architecture created by the invention. and / or therapeutic active substance in the subsequent release stage via chemical change the effective release of the reserve, a single series of events that directly and necessarily follow one another. It does not cause a control event. It occurred in the previous oscillation stage. physical and / or chemical change, access interface between relevant levels 30 through the sequential access regulation structure (25) of the following oscillation stage microenvironmental accessibility is changing the situation; however, the accessibility in question the change, followed by a direct, simultaneous and subsequent reserve of the therapeutic active substance. 40 This does not mean that it will be released uncontrollably. It will become accessible. effective release of the therapeutic active substance reserve in the subsequent release phase the transition, additional transition created by the interstage oscillation delay barrier (28) oscillation sensitive to microenvironmental conditions associated with the oscillation stage in question, depending on its resistance. The physical and / or chemical behavior of the regulatory structure, the relevant selective release barrier 5 via the transition feature and the transmission characteristic of the associated controlled oscillation transition channel It is also regulated. The stepped oscillation control layer (27) has different oscillations. the general therapeutic active substance delivery behaviors of the levels relative to each other contributes to the regulation and preservation of separate oscillation characteristics. This ensures that the physical and / or 10 that occurred in the previous oscillation stage are compensated for. chemical change, subsequent release stage becoming microenvironmentally accessible and the reserve of the therapeutic active substance at that release stage to effective release passing through, functionally related to each other but technically distinct from each other It creates separate control stages; the release sequence of the therapeutic active substance. only the physical locations of the reserves within the nano-carrier main body (2) or 15 not a passive delay dependent on the passage of time, but a defined delay created between levels Access is regulated based on the relationship between transmission and delay. In this context, a stepped drug delivery system guided by a magnetic field (1); nano- magnetically in the direction of the carrier main body (2) component to the target tissue region (35) control of the microenvironment of the target tissue region (35) microenvironment input 20 Interaction with the release architecture via channel (26), first therapeutic active substance reserve (9), second therapeutic active substance reserve (15) and third therapeutic active substance the reserve (21) components are kept in separate release stages, The subject is oscillation stages and oscillation regulation structures sensitive to microenvironmental conditions. and controlled via selective oscillation barriers, 25 oscillation stages in one oscillation phase the change that occurred inter-level access interfaces and inter-level sequential access to the next oscillation stage through the access regulation structure (25) changing its state and transitioning to the effective oscillation of the subsequent oscillation stage further regulation via the interstage oscillation delay barrier (28) By means of spatial targeting, temporal and phased therapeutic active substance release 30 It integrates its control within the same technical system. Industrial Application of the Invention: 41 The invention describes a magnetic field-driven, microenvironmentally sensitive, and stepped system. and / or nano-carrier systems that provide sequential release of therapeutic active substances; nanotechnology, pharmaceutical technology, biomaterial technologies, targeted in the production of therapeutic active substance delivery systems and controlled release systems It can be produced through the industrial production methods used, is repeatable and different 5 It is configurable according to therapeutic application requirements. The system is formed magnetic components, biocompatible carrier structures, therapeutic active substance reserves, microenvironmentally sensitive release regulation structures, selective release barriers, controlled oscillation transition channels, inter-level access interfaces, Inter-stage sequential access management structure, inter-stage oscillation delay 10 barrier, stepped release control structures, biocompatible protective coating and surface Stabilization structures are prepared in separate production stages and / or integrated production. created within the processes and functionally within the same nano-carrier architecture. They can be assembled. In this production architecture, only the oscillation chambers Not only were they physically separated from each other, but they also remained in the previous oscillation stage 15 the subsequent release stage of the physical and / or chemical change that occurs inter-level access that enables changing the microenvironmental accessibility status the transition of the therapeutic active substance reserve to the effective release state following its relationship also the delay relationship between the regulating levels in the production phase This can be achieved. In this way, magnetic positional control, dependent on microenvironmental conditions, is 20 activation, sequential access between stages and the delivery of the therapeutic active substance also The regulation of functions can be performed using a fabricable, repeatable nano-carrier architecture. These features can be transformed into functional characteristics. The invention is manufactured using biocompatible polymeric materials and lipid-based carrier materials. inorganic carrier materials, organic-inorganic composite materials and the aforementioned 25 Combinations of materials suitable for nano-carrier production can be used. Nano-structures that provide magnetic properties are placed in a defined region within the carrier system. It can be positioned in a way that allows it to be held, secured, and contained; therapeutic active substance reserves structurally and / or functionally separated from each other Therapeutic active substances can be loaded into release chambers, and the said release is 30 compartments with microenvironmentally sensitive oscillation regulation structures, selective oscillation. barriers, controlled oscillation transition channels, inter-level access interfaces, Inter-stage sequential access control structure, staged oscillation control layer, and 42 structural and functional relationships defined by interstitial oscillation delay barrier This can be achieved within the framework of the materials used in the production of these structures. compositions, geometric properties, relative positions, permeability, their responses to microenvironmental conditions and their resistance to therapeutic active substance delivery By determining the resistances they create, the 5 that occurred in the previous oscillation stage are analyzed. the change affects the accessibility status of the subsequent oscillation stage and the therapeutic active ingredient in the subsequent release phase that becomes available The oscillation architecture, in which the transmission is also regulated, is repeatable. This allows for the creation of magnetic guidance and target retention capabilities. with phased and / or sequential release of therapeutic active substance depending on microenvironmental conditions, 10 not as behaviors that randomly emerge after production, but as nano-carriers as the technical specifications determined and controllable during the production phase of its architecture It can be created. Particle formation, encapsulation, and matrix generation in the creation of nano-carrier systems. creation, layering, coating, surface preparation, surface 15 Functionalization, therapeutic active substance loading, magnetic nanostructures Placement in a carrier matrix, pore formation, creation of a controlled passage, Other physical and / or chemical applications suitable for barrier formation and nano-carrier production. Production methods can be used individually or in combination. The methods to be used... The production method depends on the physical and chemical properties of the nano-carrier material and the 20 to be transported. the properties of the therapeutic active substance, the structure of the magnetic component to be used, the targeted microenvironmental response mechanism, the number of release stages, and This can be determined according to the predicted delivery characteristics of the therapeutic active substance. The industrial production of the nano-carrier system described in the invention is possible only by combining different components in the same way. It is not based on assembling them within a nano-carrier. The production process involves 25 the relative position of therapeutic active substance release chambers, between levels Structural characteristics of access interfaces, the relevant oscillation chambers of the microenvironment. the passageways that enable access, the permeability characteristics of selective oscillation barriers, Controlled oscillation transition channels' transmission resistances, sequential access between stages. The impact of the regulatory structure on the accessibility status of the subsequent oscillation stage, 30 overall transmission of different oscillation stages of the stepped oscillation control layer its effect on behavior and subsequent therapeutic implications of the interstitial oscillation delay barrier. Additional transition resistance created by the active substance reserve to the transition to effective release. 43 This can be determined through production parameters. Thus, an oscillation the subsequent release of physical and / or chemical changes occurring at this stage changing access to the microenvironment at the level of accessibility in question direct release of the therapeutic active substance reserve following the change this does not mean that the subsequent delivery of the therapeutic active substance occurs between 5 stages. oscillation regulation, barrier and transition structures related to oscillation delay barriers. Nano-carrier architecture repeatable manufacturing processes, also regulated by It can be created within it. Functional differences between oscillation stages are achieved through production parameters. It can be determined. The material composition and thickness of structures sensitive to microenvironmental conditions, 10 Response threshold and response speed; permeability and physical integrity of selective oscillation barriers; Cross-sectional area, length, porosity, and transmission resistance of controlled flow paths; Thickness, permeability, dissolution behavior, and swelling of interstitial retardation structures. Its behavior and / or diffusion resistance can be altered during the manufacturing process. This Successive oscillations by controlled determination of parameters 15 Different therapeutic active substance delivery rates between stages, different release onset Conditions and different oscillation durations can be created. The number of therapeutic active substance release sites within the nano-carrier system is determined by the word... the amount of therapeutically active substance transported in the regions in question, therapeutically active substance concentration, geometric arrangement of oscillation zones, sensitive to microenvironmental conditions 20 response characteristics of structures, transition characteristics of selective oscillation barriers, controlled oscillation transition path transmission resistances and retardation characteristics between stages It can be customized during the production phase according to the intended use. This structure, By preserving the basic nano-carrier architecture, different therapeutic agents can be applied to different surfaces. 25 release profiles, different target areas and different therapeutic application requirements It enables the development of products aimed at this purpose. Therapeutic active ingredient reserves contain different quantities and / or of the same therapeutic active ingredient. They can be prepared to include different concentrations, as well as different therapeutic options. It can also be produced to include the active ingredients. Therefore, the system is a single unit. 30 controlled release stages of the therapeutic active substance In addition to delivery, multiple therapeutic active substances are released in a specified release sequence. and in the development of products for transportation according to different transport characteristics It is also suitable for use. The number of oscillation stages is also limited to a certain number. 44 without limitation, the structural and functional requirements of the targeted therapeutic release profile. It can be arranged during the production phase in a way that ensures functional differentiation. The amount of magnetically enhancing components, their distribution within the nano-carrier, and Its position is adjusted during the production phase by the external magnetic field of the nano-carrier system. The interaction behavior can be determined. Thus, the nano-carrier's interaction with the target region can be assessed. redirection, increasing density around the target area and / or a specific magnetic properties necessary for maintaining the target area for a certain period of time during the production phase It is possible to create it. External tools used for magnetic guidance. The magnetic field generation system can be produced independently of the nano-carrier, and It can be functionally associated with the nano-carrier system during use. 10 Generating and directing an external magnetic field in the target area. Components for concentration; permanent magnet, electromagnetic field generation. the device to create a magnetic field orientation structure and / or magnetic field gradient It can be produced using suitable technical arrangements. External magnetic system its geometric structure, magnetic field strength, field direction, and the 15 it creates in the target region magnetic field distribution, magnetic properties of the nano-carrier to be used and the targeted magnetic field distribution It can be adjusted according to the terms of use. In this way, nano-carrier production is possible. Production of an external magnetic system that provides positional control of the nano-carrier. It can be carried out in independent industrial processes and the final system It can be functionally integrated within it. 20 The surface properties of the nano-carrier system can also be modified during industrial production. It has the following characteristics: biocompatible protective coating, surface stabilization structure, and, if necessary. Targeting functional surface components of nano-carriers in the biological environment considering physical stability, surface behavior and interaction characteristics with the target area These structures can be created by adding them to a nano-carrier, thus improving the microenvironment. a passage that allows controlled entry of the medium and controlled exit of the therapeutic active substance This can be done in a way that preserves the function of these regions. The production process of the system described in the invention involves nano-carrier size, particle distribution, and surface area. properties, amount of magnetically active component, amount of therapeutic active substance loading, structural integrity of oscillation compartments, characteristics of barrier and transition structures and 30 Technical parameters such as response to microenvironmental conditions are used in production and quality control. These characteristics are identifiable and traceable in the processes. This situation is consistent with the same technical architecture. repeating the process within the specified production tolerances, between production batches 45 checking structural and functional characteristics and the system's target product This allows for standardization according to their characteristics. The system described in the invention facilitates the distribution of the therapeutic active substance to off-target sites. the restriction of the nano-carrier carrying the therapeutic active substance in the target region concentration and / or retention and release of the therapeutic active substance target 5 carried out in a controlled manner depending on the microenvironmental characteristics of the region It can be used in the development of pharmaceutical and biomedical products for which it is intended. It is characterized by its targeted therapeutic active substance delivery systems and controlled processes. drug delivery systems, multi-stage drug delivery platforms and sequential Nano-carrier 10, where the creation of therapeutic active substance delivery stages is necessary. It can be applied to various technologies. The invention specifically addresses the relationship between pH, redox conditions, and the surrounding biological environment in the target region. other methods that can be used in controlling enzymatic activity, temperature and / or therapeutic release It can be adapted to applications where microenvironmental differences exist. Tumor While tissues constitute one of these application areas, the manufacturability of the invention and 15 industrial applicability to a specific disease, a specific tissue, a specific microenvironment the condition, with a specific therapeutic active substance or a specific carrier material It is not restricted. The stepwise and / or sequential oscillation behavior of the nano-carrier system is only specific to a particular period. It is not specific to the therapeutic application; the basic supporting architecture is preserved while maintaining therapeutic effectiveness. material reserves, microenvironmental response characteristics, transition resistances, and retardation The ability to modify their behavior, tailored to different product requirements of the same technical platform. This allows for its configuration according to the system described in the invention. Thus, the system in question is a single system. Beyond being a structure specific to the final product, it involves different therapeutic active ingredients and different target groups. a nano-carrier platform technology with adjustable production parameters for different regions 25 This can be evaluated on an industrial scale. The fact that the essential components required for the invention can be produced separately, the same nano-carrier architecture through controlled manufacturing stages of the components in question its integration within, structural and functional differences between oscillation levels relationships can be defined through production parameters and the magnetic 30 of the nano-carrier The invention allows for the separate production of external system components for positional control. This allows for the transfer of production processes to a scale that is not limited to laboratory levels. It provides. 46 In conclusion, the nano-carrier system described in this invention consists of manufacturable components. the arrival of structural and functional relationships between components during the production phase the ability to define and repeatable technical specifications in different production batches the suitability of creating, production parameters of the targeted therapeutic Adaptable to application, pharmaceutical and biomedical product development 5 can be transferred to existing nano-carriers, biomaterials, coatings, surfaces functionalization, therapeutic active substance loading, and magnetic field generation. Because it can be realized with these technologies, it is applicable to industry. Magnetic positional control, microenvironmental condition-dependent activation, inter-stage Access regulation and controlled delivery of therapeutic active substance are based on the same technical architecture. 10 integration within it; the system is scalable according to different therapeutic needs, in the development of configurable and repeatable nano-carrier products It enables its use.

Claims

47 REQUESTS 1. The invention relates to the controlled, stepwise and / or sequential release of a therapeutically active substance. a stepwise drug release system (1) is directed by a magnetic field. Its characteristic feature is that it incorporates therapeutic active substance delivery and release structures. nano-carrier main body (2), located within the nano-carrier main body (2) and 5 nano-carrier main body (2) component under the influence of external magnetic field to direct, position, concentrate and / or hold magnetic nanoparticles that provide magnetic properties (4), nano- structurally and / or functionally separated from each other within the carrier main body (2). first therapeutic active substance release compartment (8) and second therapeutic active substance 10 release compartment (14), inside the first therapeutic active substance release compartment (8) the first therapeutic active substance reserve (9), the second therapeutic active substance The second therapeutic active substance reserve (15) is located in the release chamber (14), the first therapeutic active substance release compartment (8) is functionally related to the first microenvironmentally sensitive release regulation structure (10), second therapeutic effective 15 the second microenvironmental condition functionally associated with the substance release compartment (14) responsive release regulation structure (16), first therapeutic active substance release located between compartment (8) and the second therapeutic active substance release compartment (14) first-stage inter-access interface (13), nano-carrier main body (2) 20 within the nano-carrier main body (2) of the surrounding microenvironment Microenvironmental input for controlled interaction with oscillation architecture channel (26), first therapeutic active substance release chamber (8) and / or first microenvironmental condition sensitive release regulation structure (10) physical and / or chemical changes occurring depending on microenvironmental conditions Depending on the change, the second therapeutic active substance release compartment (14) component 25 inter-level in a way that will change the microenvironmental accessibility situation inter-level sequential access functionally related to the access interface (13) regulatory structure (25) and second therapeutic active substance release chamber (14) after the microenvironment becomes accessible Additional and control of the transition of active substance reserve (15) component to effective release 30 interstages structured to create a manageable transition resistance Including oscillation delay barrier (28); sequential access arrangement between levels The components of the structure (25) and the interstage oscillation delay barrier (28), second microenvironmental accessibility of the therapeutic active substance release compartment (14) component 48 effective release of the second therapeutic active substance reserve (15) component with its becoming the transition between separate but functionally related control states by having a structural and functional relationship arranged in such a way as to form It is characterized by...

2. The magnetic field-guided stepped drug delivery system (1) is in accordance with claim 1 and 5 Feature; nano-carrier main body (2) contains magnetic nanoparticles (4) magnetic core carrier compartment (3) containing the components, magnetic special nanoparticles (4) magnetic core carrier compartment of components (3) to be kept in the position determined inside and outside the nano-carrier main body (2) magnetic 10 that ensures their unwanted separation is limited. nanoparticle fixation matrix (5), magnetic core carrier compartment (3) creating a structural boundary between the therapeutic active substance release architectures. magnetic core containment layer (6) and nano-carrier main body (2) preserving the relative positions of the functional areas within it and Internal carrier 15 aimed at limiting unwanted direct transfer of substances It is characterized by having a support layer (7).

3. The stepped drug delivery system guided by magnetic field (1) is in accordance with claim 1. its feature; the first therapeutic active substance reserve (9) component of the first therapeutic active substance first for controlled transfer through the substance release compartment (8) controlled release transition channel (11) and primary therapeutic active substance reserve (9) 20 uncontrolled transfer of a component before the targeted microenvironmental condition is met limiting, first microenvironmental condition sensitive release regulation structure (10) characterized by containing the first selective release barrier (12) which is functionally related to it. is being done.

4. According to claim 1, the stepped drug delivery system guided by magnetic field (1) is 25 its feature; the second therapeutic active substance reserve (15) component of the second therapeutic active substance second for controlled transfer through the substance release compartment (14) controlled release transition channel (17) and second therapeutic active substance reserve (15) uncontrolled release of the component outside the second therapeutic active substance release chamber (14) emission regulation sensitive to a second microenvironmental condition, limiting its transmission 30 by containing a second selective oscillation barrier (18) which is functionally related to its structure (16) It is characterized by...

5. According to claim 1, a stepped drug delivery system guided by a magnetic field (1) Its feature is the release chamber of the second therapeutic active substance (14) followed by release. 49 the third therapeutic active substance release chamber (20) which constitutes the stage located between and inside the second therapeutic active substance release chamber (14) third therapeutic depending on the physical and / or chemical change that occurs microenvironmental access to the active substance release compartment (20) 5 by including the second level inter-level access interface (19) for modification. It is characterized by...

6. According to claim 5, a stepped drug delivery system guided by a magnetic field (1) Its feature is that the third therapeutic active substance release chamber (20) contains the third therapeutic active substance reserve (21), third therapeutic active substance release chamber (20) Functionally related to the third microenvironmental condition sensitive release 10 regulatory structure (22), third therapeutic active substance reserve (21) component third controlled oscillation transition channel (23) for controlled transfer and third the third therapeutic active substance release component of the therapeutic active substance reserve (21) third microenvironmental limiting uncontrolled transfer outside compartment (20) The third 15 is functionally related to the condition-sensitive oscillation regulation structure (22). It is characterized by containing a selective release barrier (24).

7. Magnetic field-guided stepped drug delivery system according to claim 6 (1) and its feature is the inter-level sequential access management structure (25) component. functionally related to the second level access interface (19) and physical and / or 20 associated with the second therapeutic active substance release chamber (14) third therapeutic active substance release chamber (20) depending on chemical change in a way that will change the microenvironmental accessibility status of its component It is characterized by its organization.

8. Magnetic field-guided stepped drug delivery system according to claim 7 (1) and its feature is that the interstage oscillation delay barrier (28) component, 25 the third therapeutic agent that becomes accessible in terms of microenvironment substance release compartment (20) and third therapeutic active substance reserve (21) an additional and controllable transition resistance between the effective oscillation of its component It is characterized by being arranged in a way that will create 9. According to claim 1, the stepped drug delivery system guided by magnetic field (1) is 30 Its feature is; first therapeutic active substance release chamber (8) and second therapeutic active Therapeutic active substance transfer to the components of the substance release compartment (14) structural separation of pathways, defined delivery of therapeutic active substance carried out via transition paths and different oscillation levels 50 Step-by-step towards preserving distinct oscillation characteristics It is characterized by having an oscillation control layer (27).

10. According to claim 1, a stepped drug delivery system guided by a magnetic field (1) feature; nano-carrier main body of the microenvironmental environment inlet channel (26) component. (2) the surrounding liquid medium, ions, molecules and / or microenvironmental conditions 5 nano-carrier main body representing physical or chemical agents (2) to the relevant microenvironmental condition-sensitive emission regulation structures within It is characterized by creating a defined entry path that allows controlled access. is being done.

11. Magnetic field-guided stepped drug delivery system (1) according to claim 10 Its feature is; first microenvironmental condition sensitive release regulation structure (10) and second microenvironmental condition sensitive release regulation structure (16) components at least one of them pH, temperature, redox condition, enzymatic activity and / or target tissue microenvironmental differences between the region (35) and the non-target biological environment physical and / or chemical behavior depending on at least one of the variables 15 It is characterized by its structure that is adaptable and changeable. According to claim 12, the stepped drug delivery system is guided by a magnetic field (1). The feature is the permeability of the interstage oscillation delay barrier (28) component, thickness, pore structure, dissolution behavior, swelling properties, microenvironmental conditions through at least one of the following characteristics: response and / or diffusion resistance the transition behavior between therapeutic active substance release chambers and / or subsequent therapeutic efficacy becoming accessible in terms of microenvironment effective release of the therapeutic active substance reserve located in the substance release chamber structuring it in a way that will regulate the transition resistance created against the transition It is characterized by 25. According to claim 13, the stepped drug delivery system is guided by a magnetic field (1). feature; permeable component of the sequential access arrangement structure between levels (25) intermediate zone, physical transition channel, microenvironmentally sensitive transition zone, at least one of the following: soluble structure, swellable structure and / or porous transition zone will include and depend on the physical and / or chemical change in a release stage 30 in a way that will alter the microenvironmental access to the subsequent emission stage It is characterized by its structure. According to claim 14, the stepped drug delivery system is guided by a magnetic field (1). Its feature is; nano-carrier main body (2) on the outer circumference, with nano-carrier main body (2) 51 nano-carriers that create a biocompatible interface between biological environments. uncontrolled direct contact of the functional components inside the main body (2) with the external environment with a biocompatible outer protective coating layer (29) that limits contact on the biocompatible outer protective coating layer (29) and / or the said integrated with a biocompatible outer protective coating layer (29), 5 nano-carrier main body (2) components are undesirable in the biological environment limiting clustering and supporting dispersion stability It is characterized by containing a surface stabilization layer (30).

15. Magnetic field-guided stepped drug delivery system according to claim 14 (1) its feature is that it is located on the nano-carrier main body (2) and the target tissue region 10 (35) to bind to and / or selectively interact with biological structures associated with those structures. Surface binders with targeting function for creating interaction (31) It is characterized by its inclusion. According to claim 16, the stepped drug delivery system is guided by a magnetic field (1). its feature is that it produces a magnetic effect on magnetic nanoparticles (4) 15 external magnetic field generating unit (32), which creates the magnetic field that will bring about the generated magnetic field is arranged in the direction of the target tissue region (35) magnetic field guiding element (33) and the generated magnetic field concentration around the target tissue region (35) and / or target tissue region Magnetic field 20 for increasing the magnetic field gradient in the direction (35). It is characterized by containing a condensing element (34).

17. Magnetic field-guided stepped drug delivery system according to claim 16 (1) Its feature is; external magnetic field generating unit (32), magnetic field between the guiding element (33) and the magnetic field concentrating element (34) the relationship, magnetic properties of 25 within the nano-carrier main body (2) Magnetic effect on nanoparticles (4) in the direction of the target tissue region (35) by creating the nano-carrier main body (2) component target tissue region (35) to be directed around the target tissue region (35) suitable for concentration and / or retention around the target tissue region (35) It is characterized by being arranged in such a way as to be. 30 According to claim 18, the stepped drug delivery system is guided by a magnetic field (1). Its feature is the stepped oscillation architecture inside the nano-carrier main body (2). the therapeutic active substance transferred through the nano-carrier main body (2) outside 52 with its controlled oscillation outlet opening (36) for controlled transfer It is characterized by...

19. Magnetic field-guided stepped drug delivery system according to claim 6 (1) and its characteristic is; first therapeutic active substance reserve (9), second therapeutic active substance the same 5 components of the reserve (15) and the third therapeutic active substance reserve (21) different amounts of the therapeutic active substance and / or will contain concentrations or different therapeutic active substances the first therapeutic active substance release chamber will occur in sequence. (8), second therapeutic active substance release chamber (14) and third therapeutic active The substances must be separated from each other within the substance release compartment (20) 10 It is characterized by...

20. Magnetic field-guided stepwise drug delivery system according to claim 6 (1) Its feature is; first microenvironmental condition sensitive release regulation structure (10), second microenvironmental condition sensitive release regulation structure (16) and third microenvironmentally sensitive release regulation structure (22) components of the same 15 different response thresholds and / or different responses to microenvironmental variables will respond at different speeds or react to different microenvironmental variables It is characterized by being structured in a way that will deliver results.

Images